{
  "entity_id": "O-000872",
  "folder": "Cancer-Australia",
  "name": "Cancer Australia",
  "type": "Non-corporate Commonwealth Entity",
  "jurisdiction": "Commonwealth",
  "portfolio": "Health, Disability and Ageing",
  "website": "http://www.canceraustralia.gov.au",
  "data_status": "rich",
  "completeness": {
    "has_strategy_brief": true,
    "has_strategy_structured": true,
    "has_vision": false,
    "has_kpi_targets": true,
    "has_kpi_results": true,
    "has_strategy_overview": true,
    "has_legislation_text": true,
    "has_legislation_structured": true,
    "has_global_initiatives_text": true,
    "has_ideas": true,
    "has_artifacts": true,
    "n_ideas": 8,
    "n_legislation": 4,
    "n_artifacts": 9,
    "n_kpi_targets": 12,
    "n_kpi_results": 12,
    "n_outcomes": 1,
    "verified_own_data": true
  },
  "strategy_profile": {
    "status": "published",
    "confidence": "high",
    "summary": "Cancer Australia’s purpose is to minimise the impact of cancer, address disparities, and improve the health outcomes of people affected by cancer in Australia by providing national leadership in cancer control. [CP p.21]",
    "official_site_url": "http://www.canceraustralia.gov.au",
    "source_documents": [
      {
        "type": "annual_report",
        "title": "Cancer Australia Annual Report 2024-25 (PDF 2.55 MB)",
        "url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "period": "2024-25",
        "confidence": "high"
      },
      {
        "type": "strategie",
        "title": "2025 APS Employee Census Action Plan (PDF 490.96 KB)",
        "url": "https://canceraustralia.gov.au/sites/default/files/2025-10/2025-aps-employee-census-action-plan.pdf",
        "period": "2025",
        "confidence": "medium"
      },
      {
        "type": "strategie",
        "title": "2024 APS Employee Census Action Plan (PDF 293.58 KB)",
        "url": "https://canceraustralia.gov.au/sites/default/files/2024-11/2024-aps-employee-census-action-plan.pdf",
        "period": "2024",
        "confidence": "medium"
      },
      {
        "type": "strategie",
        "title": "2024-2025 Annual Statement of Compliance (PDF 120.29 KB)",
        "url": "https://canceraustralia.gov.au/sites/default/files/2025-10/commonwealth-child-safe-framework-annual-statement-of-compliance-2024-2025.pdf",
        "period": "2024-25",
        "confidence": "medium"
      }
    ],
    "purpose": {
      "text": "Cancer Australia’s purpose is to minimise the impact of cancer, address disparities, and improve the health outcomes of people affected by cancer in Australia by providing national leadership in cancer control. [CP p.21]",
      "source_url": "",
      "source_page": 21,
      "source_deep_url": ""
    },
    "vision": null,
    "strategic_priorities": [
      {
        "title": "Drive the implementation of the Plan, establish cross-sector partnerships, and monitor and evaluate progress to improve ",
        "description": "Drive the implementation of the Plan, establish cross-sector partnerships, and monitor and evaluate progress to improve experiences and outcomes for all Australians affected by cancer.",
        "source_url": "",
        "source_page": 11,
        "source_deep_url": ""
      },
      {
        "title": "Facilitate and build the Australian Comprehensive Cancer Network to strengthen collaboration across jurisdictions by str",
        "description": "Facilitate and build the Australian Comprehensive Cancer Network to strengthen collaboration across jurisdictions by strengthening linkages across Comprehensive Cancer Centres and with cancer and health services to deliver optimal cancer care to all regions.",
        "source_url": "",
        "source_page": 11,
        "source_deep_url": ""
      },
      {
        "title": "Provide advice to government on new and emerging cancer issues and technologies, including rising incidence of early ons",
        "description": "Provide advice to government on new and emerging cancer issues and technologies, including rising incidence of early onset cancers and Chimeric Antigen Receptor T-cell (CAR-T) and proton beam therapy; and on population screening, including new targeted screening programs for lung cancer and melanoma.",
        "source_url": "",
        "source_page": 11,
        "source_deep_url": ""
      },
      {
        "title": "In partnership with governments and philanthropic investors, invest in cancer research priorities to support world-leadi",
        "description": "In partnership with governments and philanthropic investors, invest in cancer research priorities to support world-leading cancer control in Australia. This includes advancing Australia’s capacity to develop world-class cancer clinical trials by supporting the national Cancer Clinical Trials Groups.",
        "source_url": "",
        "source_page": 11,
        "source_deep_url": ""
      },
      {
        "title": "Drive implementation of the Genomics Framework, including through the Cancer Genomics Clinical Trials Fund, to stimulate",
        "description": "Drive implementation of the Genomics Framework, including through the Cancer Genomics Clinical Trials Fund, to stimulate advancements in genomic medicine and ensure equitable access to cancer clinical trials incorporating genomics.",
        "source_url": "",
        "source_page": 11,
        "source_deep_url": ""
      },
      {
        "title": "Embed consistent, high-quality and evidence-based care for people with cancer by implementing the OCP Framework through ",
        "description": "Embed consistent, high-quality and evidence-based care for people with cancer by implementing the OCP Framework through developing, updating, improving awareness and driving uptake of OCPs, to successfully integrate OCPs into routine cancer care.",
        "source_url": "",
        "source_page": 11,
        "source_deep_url": ""
      },
      {
        "title": "Provide national leadership and support to improve the national collection, analysis, linkage, use and benchmarking of c",
        "description": "Provide national leadership and support to improve the national collection, analysis, linkage, use and benchmarking of cancer data through the implementation of the Data Framework.",
        "source_url": "",
        "source_page": 11,
        "source_deep_url": ""
      },
      {
        "title": "Co-design and partner with Aboriginal and Torres Strait Islander communities and organisations to deliver improved cance",
        "description": "Co-design and partner with Aboriginal and Torres Strait Islander communities and organisations to deliver improved cancer outcomes and experiences for Aboriginal and Torres Strait Islander people.",
        "source_url": "",
        "source_page": 11,
        "source_deep_url": ""
      },
      {
        "title": "Lead Australia’s engagement with global cancer control partners, particularly in the Asia-Pacific region, and utilise th",
        "description": "Lead Australia’s engagement with global cancer control partners, particularly in the Asia-Pacific region, and utilise that international expertise and information to inform priority areas of work.",
        "source_url": "",
        "source_page": 11,
        "source_deep_url": ""
      }
    ],
    "values": [
      {
        "name": "national leadership in cancer control",
        "description": "",
        "source_url": "",
        "source_page": null
      },
      {
        "name": "evidence-based best practice cancer care",
        "description": "",
        "source_url": "",
        "source_page": null
      },
      {
        "name": "cancer research",
        "description": "",
        "source_url": "",
        "source_page": null
      },
      {
        "name": "national cancer data capacity",
        "description": "",
        "source_url": "",
        "source_page": null
      },
      {
        "name": "consumer and health professional cancer information",
        "description": "",
        "source_url": "",
        "source_page": null
      }
    ],
    "outcomes": [
      {
        "name": "Outcome 1: Health Policy, Access and Support",
        "description": "Minimised impacts of cancer, including through national leadership in cancer control with targeted research and clinical trials; evidence informed clinical practice; strengthened national data capacity; community and consumer information and support.",
        "activities": [
          "Provide national leadership in cancer control",
          "Develop and promote evidence-based best practice cancer care",
          "Fund cancer research and drive efforts to strengthen national data capacity in consultation with relevant agencies",
          "Provide consumer and health professional cancer information and resources"
        ],
        "source_url": "",
        "source_page": 26,
        "source_deep_url": ""
      }
    ],
    "performance_measures": [
      {
        "code": "CCE01",
        "measure": "Australian Brain Cancer Mission funding",
        "target": "At least $172 million over 10 years",
        "latest_result": "Achieved",
        "status": "Achieved",
        "target_source_url": "",
        "target_source_page": 9,
        "result_source_url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "result_source_page": 29
      },
      {
        "code": "CCE02",
        "measure": "National Lung Cancer Screening Program implementation",
        "target": "Develop clinical program elements, participant and healthcare professional resources, enhanced data linkage, and a dedicated research initiative",
        "latest_result": "Achieved",
        "status": "Achieved",
        "target_source_url": "",
        "target_source_page": 9,
        "result_source_url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "result_source_page": 30
      },
      {
        "code": "CCE03",
        "measure": "Optimal Care Pathways Framework",
        "target": "Standardised approach for developing, updating, and integrating OCPs into cancer care",
        "latest_result": "Achieved",
        "status": "Achieved",
        "target_source_url": "",
        "target_source_page": 9,
        "result_source_url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "result_source_page": 28
      },
      {
        "code": "CCE04",
        "measure": "National Framework for Genomics in Cancer Control",
        "target": "Equitable access to genomics-guided personalised cancer care",
        "latest_result": "Achieved",
        "status": "Achieved",
        "target_source_url": "",
        "target_source_page": 9,
        "result_source_url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "result_source_page": 29
      },
      {
        "code": "CCE05",
        "measure": "National Cancer Data Framework",
        "target": "Strategic direction for the collection, management, use and ongoing development of comprehensive and consistent health and cancer data",
        "latest_result": "Achieved",
        "status": "Achieved",
        "target_source_url": "",
        "target_source_page": 9,
        "result_source_url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "result_source_page": 28
      },
      {
        "code": "CCE06",
        "measure": "Improved health outcomes for Aboriginal and Torres Strait Islander people",
        "target": "Access to culturally safe mainstream cancer services, building research sector capacity, and supporting the growth of the Aboriginal and Torres Strait Islander cancer workforce",
        "latest_result": "Achieved",
        "status": "Achieved",
        "target_source_url": "",
        "target_source_page": 9,
        "result_source_url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "result_source_page": 31
      },
      {
        "code": "CCE07",
        "measure": "Cancer Australia Research Initiative",
        "target": "Fund cancer research in areas of unmet and emerging need",
        "latest_result": "Achieved",
        "status": "Achieved",
        "target_source_url": "",
        "target_source_page": 9,
        "result_source_url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "result_source_page": 32
      },
      {
        "code": "CCE08",
        "measure": "Genomics Framework implementation",
        "target": "Advancements in genomic medicine and equitable access to cancer clinical trials incorporating genomics",
        "latest_result": "Achieved",
        "status": "Achieved",
        "target_source_url": "",
        "target_source_page": 9,
        "result_source_url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "result_source_page": 29
      },
      {
        "code": "CCE09",
        "measure": "Optimal Care Pathways uptake",
        "target": "Successfully integrate OCPs into routine cancer care",
        "latest_result": "",
        "status": "",
        "target_source_url": "",
        "target_source_page": 9,
        "result_source_url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "result_source_page": null
      },
      {
        "code": "CCE10",
        "measure": "National Cancer Data Framework implementation",
        "target": "Improve national collection, analysis, linkage, use and benchmarking of cancer data",
        "latest_result": "",
        "status": "",
        "target_source_url": "",
        "target_source_page": 9,
        "result_source_url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "result_source_page": null
      },
      {
        "code": "CCE11",
        "measure": "Collaboration with Aboriginal and Torres Strait Islander communities",
        "target": "Deliver improved cancer outcomes and experiences for Aboriginal and Torres Strait Islander people",
        "latest_result": "",
        "status": "",
        "target_source_url": "",
        "target_source_page": 9,
        "result_source_url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "result_source_page": null
      },
      {
        "code": "CCE12",
        "measure": "Global cancer control partnerships",
        "target": "Utilise international expertise to inform priority areas of work",
        "latest_result": "",
        "status": "",
        "target_source_url": "",
        "target_source_page": 9,
        "result_source_url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "result_source_page": null
      },
      {
        "code": "",
        "measure": "Optimal Care Pathways uptake",
        "target": "",
        "latest_result": "Achieved",
        "status": "Achieved",
        "target_source_url": "",
        "target_source_page": null,
        "result_source_url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "result_source_page": 28
      },
      {
        "code": "",
        "measure": "National Cancer Data Framework implementation",
        "target": "",
        "latest_result": "Achieved",
        "status": "Achieved",
        "target_source_url": "",
        "target_source_page": null,
        "result_source_url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "result_source_page": 28
      },
      {
        "code": "",
        "measure": "Collaboration with Aboriginal and Torres Strait Islander communities",
        "target": "",
        "latest_result": "Achieved",
        "status": "Achieved",
        "target_source_url": "",
        "target_source_page": null,
        "result_source_url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "result_source_page": 32
      },
      {
        "code": "",
        "measure": "Global cancer control partnerships",
        "target": "",
        "latest_result": "Achieved",
        "status": "Achieved",
        "target_source_url": "",
        "target_source_page": null,
        "result_source_url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "result_source_page": 33
      }
    ],
    "document_alignment_terms": {
      "must_support": [
        "Cancer Australia’s purpose is to minimise the impact of cancer, address disparities, and improve the health outcomes of people affected by cancer in Australia by providing national",
        "Drive the implementation of the Plan, establish cross-sector partnerships, and monitor and evaluate progress to improve experiences and outcomes for all Australians affected by cancer.",
        "Facilitate and build the Australian Comprehensive Cancer Network to strengthen collaboration across jurisdictions by strengthening linkages across Comprehensive Cancer Centres and with cancer and health services to deliver optimal cancer care to all regions.",
        "Provide advice to government on new and emerging cancer issues and technologies, including rising incidence of early onset cancers and Chimeric Antigen Receptor T-cell (CAR-T) and proton beam therapy; and on population screening, including new targeted screening programs for lung cancer and melanoma.",
        "In partnership with governments and philanthropic investors, invest in cancer research priorities to support world-leading cancer control in Australia. This includes advancing Australia’s capacity to develop world-class cancer clinical trials by supporting the national Cancer Clinical Trials Groups.",
        "Drive implementation of the Genomics Framework, including through the Cancer Genomics Clinical Trials Fund, to stimulate advancements in genomic medicine and ensure equitable access to cancer clinical trials incorporating genomics.",
        "Embed consistent, high-quality and evidence-based care for people with cancer by implementing the OCP Framework through developing, updating, improving awareness and driving uptake of OCPs, to successfully integrate OCPs into routine cancer care.",
        "Provide national leadership and support to improve the national collection, analysis, linkage, use and benchmarking of cancer data through the implementation of the Data Framework.",
        "Co-design and partner with Aboriginal and Torres Strait Islander communities and organisations to deliver improved cancer outcomes and experiences for Aboriginal and Torres Strait Islander people."
      ],
      "watch_terms": [
        "Australian Brain Cancer Mission funding",
        "National Lung Cancer Screening Program implementation",
        "Optimal Care Pathways Framework",
        "National Framework for Genomics in Cancer Control",
        "National Cancer Data Framework",
        "Improved health outcomes for Aboriginal and Torres Strait Islander people",
        "Cancer Australia Research Initiative",
        "Genomics Framework implementation",
        "Optimal Care Pathways uptake",
        "National Cancer Data Framework implementation",
        "Collaboration with Aboriginal and Torres Strait Islander communities",
        "Global cancer control partnerships"
      ],
      "avoid_claiming_without_evidence": []
    },
    "review_note": ""
  },
  "strategy_brief_md": "# Cancer Australia — Strategy Brief\n\n**Reporting period**: 2024-25\n**Corporate plan in force**: 2025-26\n**Annual Report**: [2024-25](http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)\n\n## Our purpose / purposes\n\n> Cancer Australia’s purpose is to minimise the impact of cancer, address disparities, and improve the health outcomes of people affected by cancer in Australia by providing national leadership in cancer control. [CP p.21] [CP p.21]\n\n## How we deliver\n\n> Cancer Australia achieves its purpose by providing national leadership in cancer control; developing and promoting evidence-based, best practice cancer care; providing consumer and health professional cancer information; funding priority cancer research; and strengthening national cancer data capacity. [CP p.20] [CP p.20]\n\n## Government priorities for this department\n\n- Drive the implementation of the Plan, establish cross-sector partnerships, and monitor and evaluate progress to improve experiences and outcomes for all Australians affected by cancer. [CP p.11]\n- Facilitate and build the Australian Comprehensive Cancer Network to strengthen collaboration across jurisdictions by strengthening linkages across Comprehensive Cancer Centres and with cancer and health services to deliver optimal cancer care to all regions. [CP p.11]\n- Provide advice to government on new and emerging cancer issues and technologies, including rising incidence of early onset cancers and Chimeric Antigen Receptor T-cell (CAR-T) and proton beam therapy; and on population screening, including new targeted screening programs for lung cancer and melanoma. [CP p.11]\n- In partnership with governments and philanthropic investors, invest in cancer research priorities to support world-leading cancer control in Australia. This includes advancing Australia’s capacity to develop world-class cancer clinical trials by supporting the national Cancer Clinical Trials Groups. [CP p.11]\n- Drive implementation of the Genomics Framework, including through the Cancer Genomics Clinical Trials Fund, to stimulate advancements in genomic medicine and ensure equitable access to cancer clinical trials incorporating genomics. [CP p.11]\n- Embed consistent, high-quality and evidence-based care for people with cancer by implementing the OCP Framework through developing, updating, improving awareness and driving uptake of OCPs, to successfully integrate OCPs into routine cancer care. [CP p.11]\n- Provide national leadership and support to improve the national collection, analysis, linkage, use and benchmarking of cancer data through the implementation of the Data Framework. [CP p.11]\n- Co-design and partner with Aboriginal and Torres Strait Islander communities and organisations to deliver improved cancer outcomes and experiences for Aboriginal and Torres Strait Islander people. [CP p.11]\n- Lead Australia’s engagement with global cancer control partners, particularly in the Asia-Pacific region, and utilise that international expertise and information to inform priority areas of work. [CP p.11]\n\n## Outcomes\n\n### Outcome 1: Health Policy, Access and Support\nMinimised impacts of cancer, including through national leadership in cancer control with targeted research and clinical trials; evidence informed clinical practice; strengthened national data capacity; community and consumer information and support. [CP p.26]\n\n**Key activities:**\n- Provide national leadership in cancer control\n- Develop and promote evidence-based best practice cancer care\n- Fund cancer research and drive efforts to strengthen national data capacity in consultation with relevant agencies\n- Provide consumer and health professional cancer information and resources\n\n## Values and principles\n\n_Cancer Australia Values_\n\n- national leadership in cancer control\n- evidence-based best practice cancer care\n- cancer research\n- national cancer data capacity\n- consumer and health professional cancer information\n\n## What they will measure themselves on this year (targets from 2025-26 corporate plan)\n\n| Code | Measure | Target | Source |\n|---|---|---|---|\n| CCE01 | Australian Brain Cancer Mission funding | At least $172 million over 10 years | CP p.9 |\n| CCE02 | National Lung Cancer Screening Program implementation | Develop clinical program elements, participant and healthcare professional resources, enhanced data linkage, and a dedicated research initiative | CP p.9 |\n| CCE03 | Optimal Care Pathways Framework | Standardised approach for developing, updating, and integrating OCPs into cancer care | CP p.9 |\n| CCE04 | National Framework for Genomics in Cancer Control | Equitable access to genomics-guided personalised cancer care | CP p.9 |\n| CCE05 | National Cancer Data Framework | Strategic direction for the collection, management, use and ongoing development of comprehensive and consistent health and cancer data | CP p.9 |\n| CCE06 | Improved health outcomes for Aboriginal and Torres Strait Islander people | Access to culturally safe mainstream cancer services, building research sector capacity, and supporting the growth of the Aboriginal and Torres Strait Islander cancer workforce | CP p.9 |\n| CCE07 | Cancer Australia Research Initiative | Fund cancer research in areas of unmet and emerging need | CP p.9 |\n| CCE08 | Genomics Framework implementation | Advancements in genomic medicine and equitable access to cancer clinical trials incorporating genomics | CP p.9 |\n| CCE09 | Optimal Care Pathways uptake | Successfully integrate OCPs into routine cancer care | CP p.9 |\n| CCE10 | National Cancer Data Framework implementation | Improve national collection, analysis, linkage, use and benchmarking of cancer data | CP p.9 |\n| CCE11 | Collaboration with Aboriginal and Torres Strait Islander communities | Deliver improved cancer outcomes and experiences for Aboriginal and Torres Strait Islander people | CP p.9 |\n| CCE12 | Global cancer control partnerships | Utilise international expertise to inform priority areas of work | CP p.9 |\n\n## How they performed last year (results from 2024-25 annual report)\n\n| Code | Measure | Result | Status | Source |\n|---|---|---|---|---|\n| CCE01 | Australian Brain Cancer Mission funding | Achieved | Achieved | [AR p.29](http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=29)(http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=29) |\n| CCE02 | National Lung Cancer Screening Program implementation | Achieved | Achieved | [AR p.30](http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=30)(http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=30) |\n| CCE03 | Optimal Care Pathways Framework | Achieved | Achieved | [AR p.28](http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=28)(http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=28) |\n| CCE04 | National Framework for Genomics in Cancer Control | Achieved | Achieved | [AR p.29](http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=29)(http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=29) |\n| CCE05 | National Cancer Data Framework | Achieved | Achieved | [AR p.28](http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=28)(http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=28) |\n| CCE06 | Improved health outcomes for Aboriginal and Torres Strait Islander people | Achieved | Achieved | [AR p.31](http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=31)(http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=31) |\n| CCE07 | Cancer Australia Research Initiative | Achieved | Achieved | [AR p.32](http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=32)(http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=32) |\n| CCE08 | Genomics Framework implementation | Achieved | Achieved | [AR p.29](http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=29)(http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=29) |\n|  | Optimal Care Pathways uptake | Achieved | Achieved | [AR p.28](http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=28)(http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=28) |\n|  | National Cancer Data Framework implementation | Achieved | Achieved | [AR p.28](http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=28)(http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=28) |\n|  | Collaboration with Aboriginal and Torres Strait Islander communities | Achieved | Achieved | [AR p.32](http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=32)(http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=32) |\n|  | Global cancer control partnerships | Achieved | Achieved | [AR p.33](http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=33)(http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf#page=33) |",
  "strategy_overview_evidence_md": null,
  "internal_strategy_evidence_md": "# Cancer Australia - Strategy, Performance, and Operating Profile\n\n**Generated at**: 2026-05-09T21:57:01.460313+00:00\n**Entity ID**: O-000872\n**Entity type**: Non-corporate Commonwealth Entity\n**Jurisdiction**: Commonwealth\n**Portfolio**: Health, Disability and Ageing\n**Website**: http://www.canceraustralia.gov.au\n\n> Draft generated from scraped source material. Treat this as an evidence pack for editorial review, not a final judgement.\n\n## Source Coverage\n\n| Source type | Count |\n|---|---:|\n| annual-reports | 1 |\n| global-intelligence | 3 |\n| other-pdfs | 5 |\n| pages | 9 |\n| strategies | 3 |\n\n## Executive Readout\n\n### Purpose\n\n- [Page 8]\nWORKPLACE CONDITIONS\nVARIANCE VARIANCE\nRESPONSE SCALE % VARIANCE V FR A O R M IA N A C P E S FROM FROM EXTRA\nPOSITIVE FROM 2022 SPECIALIST SMALL SIZED\nOVERALL\nAGENCIES AGENCIES\nI feel a strong personal attachment to the APS 49 % -4 -12  -8  -5 \nI understand how my role contributes to achieving an outcome for the Australian 85 % -7  -7  -8  -7 \npublic\nI believe strongly in the purpose and objectives of the APS 81 % +5  -4 -3 -2\nVARIANCE VARIANCE\nVARIANCE\nRESPONSE SCALE % VARIANCE FROM APS FROM FROM EXTRA\nFROM 2022 SPECIALIST SMALL SIZED\nOVERALL\nAGENCIES AGENCIES\nWhat best describes your current workload?\n  Source: `other-pdfs/Employee-Census-2023-Highlights-Report-CA.pdf (https://canceraustralia.gov.au/sites/default/files/migrated-files/Employee-Census-2023-Highlights-Report-CA.pdf)`\n- It is the\nextent to which\nemployees are\nmotivated, inspired and\nenabled to improve an\norganisation's\noutcomes.\nyaS\nOverall, I am satisfied with my job 69 % -1 -6  -8  -8 \nI am proud to work in my agency 84 % +3 +6  0 -1\nI would recommend my agency as a good place to 69 % +1 -2 -5  -3\nwork\nI believe strongly in the purpose and objectives of 93 % +4 +7  +4 +2 my agency\nyatS\nI feel a strong personal attachment to my agency 64 % +12  +1 -2 -1\nI feel committed to my agency's goals 92 % +4 +6  +4 +2\nevirtS\nI suggest ideas to improve our way of doing things 94 % +1 +7  +4 0\nI am happy to go the 'extra mile' at work when 89 % -4 -2 -3 -5 \nrequired\nI work beyond what is required in my job to help my 82 % 0 +1 +1 0\nagency achieve its objectives\nMy agency really inspires me to do my best work 66 % +4 +5  +2 -1\nevery day\nPositive Neutral Negative\n  Source: `other-pdfs/2024-cancer-australia-aps-employee-census-highlights-report.pdf (https://canceraustralia.gov.au/sites/default/files/2024-11/2024-cancer-australia-aps-employee-census-highlights-report.pdf)`\n- It is the\nextent to which\nemployees are\nmotivated, inspired and\nenabled to improve an\norganisation's\noutcomes.\nyaS\nOverall, I am satisfied with my job 86 % +16  +9  +8  +7 \nI am proud to work in my agency 97 % +13  +16  +12  +9 \nI would recommend my agency as a good place to 78 % +9  +2 +1 +5 \nwork\nI believe strongly in the purpose and objectives of 97 % +4 +9  +7  +2 my agency\nyatS\nI feel a strong personal attachment to my agency 75 % +11  +10  +8  +11 \nI feel committed to my agency's goals 94 % +2 +6  +5  +3\nevirtS\nI suggest ideas to improve our way of doing things 93 % -1 +6  +4 +1\nI am happy to go the 'extra mile' at work when 93 % +4 +2 +2 +2\nrequired\nI work beyond what is required in my job to help my 83 % +1 +4 +4 +3\nagency achieve its objectives\nMy agency really inspires me to do my best work 83 % +17  +16  +14  +11 \nevery day\nPositive Neutral Negative\n  Source: `other-pdfs/highlights-report-2025-aps08380-ca.pdf (https://canceraustralia.gov.au/sites/default/files/2025-10/highlights-report-2025-aps08380-ca.pdf)`\n- [Page 136]\nIndex Auditor–General Act 1997 20\naudits\nfinancial statements 74–107\nfundraising activities 108–112\ninternal arrangements 43\nA\nAurora Education Foundation 31, 47\nabbreviations 132–133\nAusTender 46, 48\nAboriginal and Torres Strait Islander people 18\nAustralian Brain Cancer Mission 29\nclinical trial, participation in 36\nAustralian Cancer Plan 6–7, 9, 25\nco-designed cancer care 8–9, 18, 30–32\nimplementation 6–7, 9–10, 13, 27–29\nimproving health outcomes 8, 25, 30–32\nMonitoring and Evaluation Framework 27\npostgraduate scholarship program 31\nresearch grants 30–31 Australian Commission on Safety and\nstaff 55 Quality in Health Care 10\nACCN Innovations Showcase 24 Australian Comprehensive Cancer Network\n(ACCN) 6, 24, 27–28, 35\naccountability see management\nDiscussion Forum 28\nand accountability\nInnovations Showcase 24\naccountable authority 66, 77\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n\n### Role and Functions\n\n- [Page 4]\nContents\nStatement of acknowledgement b\nAbout this report b\nLetter of transmittal 1\nOverview 4\nChief Executive Officer’s review 6\nAdvisory Council Chair review 12\nCancer Australia Advisory Council 14\nAbout Cancer Australia 16\nAbout Cancer Australia 18\nPurpose 19\nFunctions and role 20\nOrganisational structure 21\nReport on performance 22\n2024–25 highlights 24\nAnnual performance statements 26\nFinancial overview 39\nManagement and accountability 40\nManagement and accountability 42\nCorporate governance 43\nManagement of human resources 49\nAppendices 70\nAppendix A: Report on financial performance 72\nAppendix B: Audited financial statements 74\nAppendix C: Acquittal audit report related to Cancer Australia fundraising activities 108\nAppendix D: Mandatory reporting information 114\nAppendix E: Cancer Australia advisory groups 120\nAppendix F: List of requirements 122\nGlossary 128\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [pages 4,5,6,7,8]\nhair review 12\nCancer Australia Advisory Council 14\nAbout Cancer Australia 16\nAbout Cancer Australia 18\nPurpose 19\nFunctions and role 20\nOrganisational structure 21\nReport on performance 22\n2024–25 highlights 24\nAnnual performance statements 26\nFinancial overview 39\nManagement and accountability 40\nManagement and accountability 42\nCorporate governance 43\nManagement of human resources 49\nAppendices 70\nAppendix A: Report on financial performance 72\nAppendix B: Audited financial statements 74\nAppendix C: Acquittal audit report related to Cancer Australia fundraising activities 108\nAppendix D: Mandatory reporting information 114\nAppendix E: Cancer Australia advisory groups 120\nAppendix F: List of requirements 122\nGlossary 128\nAbbreviations 132\nIndex 134\n2 Cancer Australia Annual Report 2024–25\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [Page 141]\nP R\npancreatic cancer 32–33 Rare Cancer Australia 34\npart-time staff 54, 62 remuneration 56, 64, 66–69\nhighly paid staff 69\nPartnerships for Culturally Safe Cancer Care\nkey management personnel 67\n(PCSCC)\nsenior executives 68\ngrant program 31\nRemuneration Tribunal Act 1973 66\npatient reported experience measures 8, 36–37\nresearch 9\npay see remuneration\ndata capacity 26, 35–37\nperformance see annual performance statements\nfunding and programs 9, 35–36\nperformance pay 57, 65 supporting strategic 25\npersonnel see staff Research and Data Advisory Group 120\nPortfolio Budget Statements (PBS) 21, 26, 43 role 20\npostgraduate scholarship program 31\nS\nPriority-driven Collaborative Cancer Research\nScheme (PdCCRS) 9\nsalaries see remuneration\nprocurement 46\nSenior Executive Service (SES) 49\nIndigenous Procurement Policy 48\nremuneration 68\nprogram structure 21\nSenior Executive Team 21\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [pages 124,125,126]\nb) Overview of the entity\n17AE(1)(a)(i) 20 A description of the role and functions of the entity.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [Page 13]\nJob satisfaction\nResponse scale % Variance from Variance from Va s r p ia e n c c ia e l i f s r t om Va e r x i t a r n a c s e m fr a o ll m\nPositive 2023 APS overall\nagencies sized agencies\nI am satisfied with the recognition I receive for doing a good job 71 % +1 +2 -1 -3\nI am fairly remunerated (e.g. salary, superannuation) for the work that I do 71 % +16  +8  +7  -4\nI am satisfied with my non-monetary employment conditions (e.g. leave, flexible 89 % +5  +7  +4 +5 \nwork arrangements, other benefits)\nI am satisfied with the stability and security of my job 89 % +7  +4 +7  +7 \nClarity and autonomy\nResponse scale % Variance from Variance from Va s r p ia e n c c ia e l i f s r t om Va e r x i t a r n a c s e m fr a o ll m\nPositive 2023 APS overall\nagencies sized agencies\n  Source: `other-pdfs/2024-cancer-australia-aps-employee-census-highlights-report.pdf (https://canceraustralia.gov.au/sites/default/files/2024-11/2024-cancer-australia-aps-employee-census-highlights-report.pdf)`\n- [Page 13]\nJob satisfaction\nResponse scale % Variance from Variance from Va s r p ia e n c c ia e l i f s r t om Va e r x i t a r n a c s e m fr a o ll m\nPositive 2024 APS overall\nagencies sized agencies\nI am satisfied with the recognition I receive for doing a good job 80 % +9  +11  +8  +6 \nI am fairly remunerated (e.g. salary, superannuation) for the work that I do 61 % -10  -5  -5  -12 \nI am satisfied with my non-monetary employment conditions (e.g. leave, flexible 87 % -2 +2 +1 +1\nwork arrangements, other benefits)\nI am satisfied with the stability and security of my job 87 % -2 +1 +4 +8 \nClarity and autonomy\nResponse scale % Variance from Variance from Va s r p ia e n c c ia e l i f s r t om Va e r x i t a r n a c s e m fr a o ll m\nPositive 2024 APS overall\nagencies sized agencies\n  Source: `other-pdfs/highlights-report-2025-aps08380-ca.pdf (https://canceraustralia.gov.au/sites/default/files/2025-10/highlights-report-2025-aps08380-ca.pdf)`\n\n### Strategic Priorities\n\n- [Page 5]\nLEADERSHIP - SES MANAGER\n YOUR\nVARIANCE VARIANCE\n SES MANAGER 68 % VARIANCE F V R A O RI M A N A C P E S FROM FROM EXTRA\nRESPONSE SCALE POSITIVE FROM 2022 SPECIALIST SMALL SIZED\nOVERALL\nLEADERSHIP AGENCIES AGENCIES\nINDEX\nSCORE +3 -1 -3 -4\nSES\nMANAGER\nTHE SES MANAGER\nSCORE ASSESSES\nHOW EMPLOYEES\nVIEW THE\nLEADERSHIP\nBEHAVIOURS OF\nTHEIR IMMEDIATE\nSES MANAGER IN\nLINE WITH THE APS\nLEADERSHIP\nCAPABILITY\nFRAMEWORK.\nreganaM\nSES\nMy SES manager clearly articulates the direction 72 % +12  +3 +1 +3\nand priorities for our area\nMy SES manager presents convincing arguments 70 % +10  +8  +4 -1\nand persuades others towards an outcome\nMy SES manager promotes cooperation within and 75 % +13  +8  +4 -2 between agencies\nMy SES manager encourages innovation and 65 % +3 0 -2 -5 \ncreativity\nMy SES manager creates an environment that 55 % 0 -8  -12  -12 \nenables us to deliver our best\n  Source: `other-pdfs/Employee-Census-2023-Highlights-Report-CA.pdf (https://canceraustralia.gov.au/sites/default/files/migrated-files/Employee-Census-2023-Highlights-Report-CA.pdf)`\n- [Page 5]\nLeadership - SES Manager\n Variance\nVariance\nYour from\n 71 % Variance from Variance from from extra small\nSES Manager Response scale Positive 2023 APS overall specialist\nsized\nagencies\nLeadership agencies\nIndex score\n+3 +1 -1 -1\nSES Manager\nThe SES Manager\nIndex assesses how\nemployees view the\nleadership\nbehaviours of their\nimmediate SES\nmanager in line with\nthe APS Leadership\nCapability\nFramework.\nreganaM\nSES\nMy SES manager clearly articulates the direction 74 % +2 +4 +2 +4\nand priorities for our area\nMy SES manager presents convincing arguments 69 % -1 +6  +1 -1\nand persuades others towards an outcome\nMy SES manager promotes cooperation within and 84 % +9  +15  +11  +9  between agencies\nMy SES manager encourages innovation and 62 % -3 -4 -6  -7 \ncreativity\nMy SES manager creates an environment that 64 % +9  -1 -5  -3\nenables us to deliver our best\n  Source: `other-pdfs/2024-cancer-australia-aps-employee-census-highlights-report.pdf (https://canceraustralia.gov.au/sites/default/files/2024-11/2024-cancer-australia-aps-employee-census-highlights-report.pdf)`\n- [Page 5]\nLeadership - SES Manager\n Variance\nVariance\nfrom\n Your 76 % Variance from Variance from from extra small\nResponse scale Positive 2024 APS overall specialist\nSES Manager agencies sized\nagencies\nIndex score\n+5  +5  +4 +4\nSES Manager\nThe SES Manager\nIndex assesses how\nemployees view the\nleadership\nbehaviours of their\nimmediate SES\nmanager in line with\nthe APS Leadership\nCapability\nFramework.\nreganaM\nSES\nMy SES manager clearly articulates the direction 78 % +4 +7  +7  +7 \nand priorities for our area\nMy SES manager presents convincing arguments 81 % +12  +17  +15  +12 \nand persuades others towards an outcome\nMy SES manager promotes cooperation within and 86 % +2 +16  +14  +9  between agencies\nMy SES manager encourages innovation and 74 % +12  +6  +6  +2\ncreativity\nMy SES manager creates an environment that 77 % +13  +9  +9  +7 \nenables us to deliver our best\n  Source: `other-pdfs/highlights-report-2025-aps08380-ca.pdf (https://canceraustralia.gov.au/sites/default/files/2025-10/highlights-report-2025-aps08380-ca.pdf)`\n- [Page 69]\nTable 4.29: Information about remuneration for key management personnel (2024–25)\nPost-employment Termination Total\nShort-term benefits benefits Other long-term benefits benefits remuneration\nOther benefits Superannuation Long service Other long-\nName Position title Base salary Bonuses and allowances contributions leave term benefits\nKeefe, Dorothy Chief Executive $430,675 $0 $122,001 $53,086 $11,487 $0 $0 $617,249\nOfficer\nHowlett, Claire Deputy CEO $325,390 $0 $79 $58,176 $8,144 $0 $0 $391,789\nWiegold, Elmer Head Corporate $205,523 $0 $0 $40,995 $4,384 $0 $0 $250,902\nOperations / CFO\nMilch, Vivienne Medical Director $235,096 $0 $25,153 $34,122 $5,965 $0 $0 $300,336\nMeredyth, David Head Cancer $227,727 $0 $21,595 $45,696 $5,965 $0 $0 $300,983\nControl Strategy\nLambert, Adam Head Evidence, $111,544 $0 $6,326 $14,717 $2,742 $0 $0 $135,329\nPriority\nInitiatives and\nCommunications\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [pages 69,70,71,72,73,74,75]\nher long-\nName Position title Base salary Bonuses and allowances contributions leave term benefits\nKeefe, Dorothy Chief Executive $430,675 $0 $122,001 $53,086 $11,487 $0 $0 $617,249\nOfficer\nHowlett, Claire Deputy CEO $325,390 $0 $79 $58,176 $8,144 $0 $0 $391,789\nWiegold, Elmer Head Corporate $205,523 $0 $0 $40,995 $4,384 $0 $0 $250,902\nOperations / CFO\nMilch, Vivienne Medical Director $235,096 $0 $25,153 $34,122 $5,965 $0 $0 $300,336\nMeredyth, David Head Cancer $227,727 $0 $21,595 $45,696 $5,965 $0 $0 $300,983\nControl Strategy\nLambert, Adam Head Evidence, $111,544 $0 $6,326 $14,717 $2,742 $0 $0 $135,329\nPriority\nInitiatives and\nCommunications\nToms, Cindy Head Evidence, $148,580 $0 $17,450 $25,787 $4,312 $0 $0 $196,129\nPriority\nInitiatives and\nCommunications\nManagement\nand\naccountability\n67\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [Page 118]\nTable D.2: Market research undertaken by Cancer Australia in 2024–25\nAmount paid\nOrganisation Service provided (GST incl)\nNil Nil –\nGrant programs\nThe following grant programs were administered by Cancer Australia during the period 1 July 2024\nto 30 June 2025:\nŪ Priority-driven Collaborative Cancer Research Scheme\nŪ Support for Cancer Clinical Trials program\nŪ Supporting People with Cancer grant program\nŪ Partnerships for Culturally Safe Cancer Care grant program\nŪ Partnerships for Cancer Research grant program.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [Page 137]\nB Chief Executive Officer 20\nsee also Keefe, Dorothy\nbest practice cancer care 18, 26, 34–35 annual review 6–10\nletter of transmittal 1\nburden of disease 18\nChief Financial Officer 21, 66, 75–77\nbusiness performance see\nfinancial performance China Anti-Cancer Association (CACA) 33\nBusiness Plan 43 classification levels of staff 56–57, 64–65\nbusiness planning 43 climate action 117\nButler MP, Hon Mark 10, 21 Clinical Policy Advice Branch 21\nclinical trials 7, 9, 21, 24, 26, 36\nC\nClosing the Gap Priority Reforms 32\nCampaign Advertising by Australian\ncode of conduct 44\nGovernment Departments and\nAgencies Report 114 Comcare 119\nCancer and Population Commonwealth Fraud and Corruption\nSteering Committee 8, 25 Control Framework 2024 43\nCancer Australia 18–21 Commonwealth Ombudsman 44\nCancer Australia Act 2006 1, 20 community organisations 31, 35\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [Page 138]\nD F\ndata capacity 36–37 financial overview 39\nDepartment of Health, Disability and Ageing financial performance 72–73\n6, 10, 24, 29, 37, 44\nfinancial statements 74–107\ntechnical assistance, provision of 30\nFirst Nations Cancer Outcomes 8, 31\ndisability reporting 42, 116\nFong, Professor Kwun 12, 15\nE Forster, Associate Professor Dion 12, 15\nfraud and corruption control 43\necologically sustainable development 42, 117\nfreedom of information 42, 116\nelectricity greenhouse gas emissions 118\nFreedom of Information Act 1982 116\nEmployee Assistance Program 119\nfull-time staff 54, 62\nemployees see staff\nfunctions 20\nEnterprise Agreement 49\nfunding partners 29\nEntity Resource Statement 72, 119\nfundraising report 108–112\nEnvironment Protection and Biodiversity\nConservation Act 1999 117\nG\nenvironmental performance 117\nequitable access 7, 9, 24, 36 G7 Cancer 33\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [Page 141]\nP R\npancreatic cancer 32–33 Rare Cancer Australia 34\npart-time staff 54, 62 remuneration 56, 64, 66–69\nhighly paid staff 69\nPartnerships for Culturally Safe Cancer Care\nkey management personnel 67\n(PCSCC)\nsenior executives 68\ngrant program 31\nRemuneration Tribunal Act 1973 66\npatient reported experience measures 8, 36–37\nresearch 9\npay see remuneration\ndata capacity 26, 35–37\nperformance see annual performance statements\nfunding and programs 9, 35–36\nperformance pay 57, 65 supporting strategic 25\npersonnel see staff Research and Data Advisory Group 120\nPortfolio Budget Statements (PBS) 21, 26, 43 role 20\npostgraduate scholarship program 31\nS\nPriority-driven Collaborative Cancer Research\nScheme (PdCCRS) 9\nsalaries see remuneration\nprocurement 46\nSenior Executive Service (SES) 49\nIndigenous Procurement Policy 48\nremuneration 68\nprogram structure 21\nSenior Executive Team 21\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- Audit and Risk Committee Charter (PDF 199.01 KB)\nCommonwealth Child Safe Framework Statement of Compliance\nCancer Australia is required to publish an annual statement of compliance under Requirement 4 of the Commonwealth Child Safe Framework\n2022-2023 Annual Statement of Compliance (PDF 94.45 KB)\n2023-2024 Annual Statement of Compliance (DOCX 33.12 KB)\n2024-2025 Annual Statement of Compliance (PDF 120.29 KB)\nCorporate Plans\nCancer Australia’s Corporate Plans are developed annually, covering a four-year period and set out the objectives and key activities Cancer Australia intends to pursue to achieve its purpose.\n  Source: `pages/corporate-plans-index.html (https://canceraustralia.gov.au/about-us/accountability-and-reporting)`\n\n## KPIs, Targets, and Where They Are At\n\n- Performance criterion 2024–25 target Criterion source Result\nInvest in community Award at least 4 grants (targeting 2 2024–25 Achieved.\nengagement to support community organisations and Corporate Plan, See below.\nevidence-based 2 Aboriginal and Torres Strait Islander page 11.\ninformation and support organisations) per annum to improve\nfor people affected outcomes and support for people\nby cancer through the affected by cancer.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [pages 38,39,40,41,42,43]\nPerformance criterion 2024–25 target Criterion source Result\nProvide high quality Maintain published data analyses 2024–25 Achieved.\ncancer data to inform and insights on the National Cancer Corporate Plan, See below.\nnational cancer control.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- Provide consumer and health professional cancer information and resources\nPerformance criterion 2024–25 target Criterion source Result\nProvide evidence-based Up-to-date evidence-based cancer 2024–25 Achieved.\ncancer information to information available on the Cancer Corporate Plan, See below.\ncancer consumers, health Australia website. page 13.\nprofessionals and the\n>5 Cancer information topics are Program 1.1\ncommunity.\nreviewed and updated.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [Page 32]\nPerformance criterion 2024–25 target Criterion source Result\nProvide technical support Collaboratively engage with key 2024–25 Achieved.\nto the Department of stakeholders to develop and deliver Corporate Plan, See below.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- Performance criterion 2024–25 target Criterion source Result\nPartner with Aboriginal Priority Aboriginal and Torres Strait 2024–25 Achieved.\nand Torres Strait Islander Islander cancer control initiatives led Corporate Plan, See below.\npeople to co-design and and co-designed by Aboriginal and page 9.\ndeliver improved cancer Torres Strait Islander people.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- Performance criterion 2024–25 target Criterion source Result\nLead delivery of 5 early Engage collaboratively with key 2024–25 Achieved.\nimplementation National stakeholders to improve pancreatic Corporate Plan,\nSee below.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- Performance criterion 2024–25 target Criterion source Result\nProvide leadership Engage collaboratively with 2024–25 Achieved.\ninternationally in international counterparts, Corporate Plan, See below.\ncancer control. including through the World Health page 10.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- Performance criterion 2024–25 target Criterion source Result\nTranslate evidence to Translate research into evidence-based 2024–25 Achieved.\ninform best practice information to assist and inform policy Corporate Plan, See below.\ncancer care. and cancer care. page 11.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- Performance criterion 2024–25 target Criterion source Result\nSupport Australia’s Fund 14 CTGs as per published grant 2024–25 Achieved.\nnational Multi-site guideline timeframes.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- Provide national leadership in cancer control\nPerformance criterion 2024–25 target Criterion source Result\nLead the implementation Engage with the cancer sector to 2024–25 Achieved.\nof the Australian Cancer communicate and promote uptake Corporate Plan, See below.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- Performance criterion 2024–25 target Criterion source Result\nDrive the implementation Implementation of the Australian Brain 2024–25 Achieved.\nof the Australian Brain Cancer Mission, in collaboration with Corporate Plan, See below.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- Performance criterion 2024–25 target Criterion source Result\nProvide high quality Maintain published data analyses 2024–25 Achieved.\ncancer data to inform and insights on the National Cancer Corporate Plan, See below.\nnational cancer control.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- Develop and promote evidence-based best practice cancer care\nPerformance criterion 2024–25 target Criterion source Result\nLead the development, Complete discovery project to test the 2024–25 Partially\ndissemination, and feasibility of digitising and integrating Corporate Plan, met.\nimplementation of the Optimal Care Pathway (OCP) for page 11.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- F und cancer research and drive efforts to strengthen national data capacity\nin consultation with relevant agencies\nPerformance criterion 2024–25 target Criterion source Result\nOversee a dedicated Award cancer research grants in areas 2024–25 Partially\nbudget for research of identified priority as per published Corporate Plan, met\ninto cancer. grant guideline timeframes. page 12.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n\n## Key Metrics\n\n| Values found | Evidence | Source |\n|---|---|---|\n| $17.317 million, 17.317 million | [Page 41]\nFinancial overview\nThe 2024–25 departmental expenses were $17.317 million (GST exclusive). | `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)` |\n| 24\nAPS, 28\nAPS, 5\nAPS, 1\nAPS, 0\nAPS | [Page 54]\nTable 4.10: Australian Public Service Act ongoing employees current reporting period (2024–25)\nMan/male Woman/female Non-binary Prefers not to answer Uses a different term Total\nFull Part Full Part Full Part Full Part Full Part\ntime time Total time time Total time time Total time time Total time time Total\nSES 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0\nSES 2 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 1\nSES 1 2 0 2 0 0 0 0 0 0 0 0 0 0 0 0 2\nEL 2 2 0 2 8 0 8 0 | `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)` |\n| 2\nAPS, 5\nAPS, 4\nAPS, 0\nAPS | [Page 55]\nTable 4.11: Australian Public Service Act non-ongoing employees current reporting period (2024–25)\nMan/male Woman/female Non-binary Prefers not to answer Uses a different term Total\nFull Part Full Part Full Part Full Part Full Part\ntime time Total time time Total time time Total time time Total time time Total\nSES 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0\nSES 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0\nSES 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0\nEL 2 0 0 0 0 0 | `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)` |\n| 26\nAPS, 33\nAPS, 9\nAPS, 1\nAPS, 0\nAPS | [Page 56]\nTable 4.12: Australian Public Service Act employees by full time and part time status\ncurrent reporting period (2024–25)\nOngoing Non-ongoing Total\nFull time Part time Total Full time Part time Total Non-\nongoing ongoing\nSES 3 0 0 0 0 0 0 0\nSES 2 1 0 1 0 0 0 1\nSES 1 2 0 2 0 0 0 2\nEL 2 10 0 10 0 0 0 10\nEL 1 19 5 24 1 1 2 26\nAPS 6 23 5 28 4 1 5 33\nAPS 5 3 2 5 3 1 4 9\nAPS 4 1 0 1 0 0 0 1\nAPS 3 0 0 0 0 0 0 0\nAPS 2 0 0 0 0 0 0 0\nAPS 1 0 0 0 0 | `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)` |\n| 25\nAPS, 22\nAPS, 6\nAPS, 0\nAPS | [Page 62]\nTable 4.20: Australian Public Service Act ongoing employees previous reporting period (2023–24)\nMan/male Woman/female Non-binary Prefers not to answer Uses a different term Total\nFull Part Full Part Full Part Full Part Full Part\ntime time Total time time Total time time Total time time Total time time Total\nSES 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0\nSES 2 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 1\nSES 1 2 0 2 1 0 1 0 0 0 0 0 0 0 0 0 3\nEL 2 2 0 2 9 0 9 | `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)` |\n| 2\nAPS, 3\nAPS, 5\nAPS, 0\nAPS | [Page 63]\nTable 4.21: Australian Public Service Act non-ongoing employees previous reporting period (2023–24)\nMan/male Woman/female Non-binary Prefers not to answer Uses a different term Total\nFull Part Full Part Full Part Full Part Full Part\ntime time Total time time Total time time Total time time Total time time Total\nSES 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0\nSES 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0\nSES 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0\nEL 2 0 0 0 0 | `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)` |\n| 2\nAPS, 3\nAPS, 5\nAPS, 0\nAPS | [pages 63,64,65,66,67,68,69]\n1 0 1 1 0 0 0 0 0 0 0 0 0 2\nAPS 6 1 0 1 1 1 2 0 0 0 0 0 0 0 0 0 3\nAPS 5 0 0 0 3 2 5 0 0 0 0 0 0 0 0 0 5\nAPS 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0\nAPS 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0\nAPS 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0\nAPS 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0\nOther 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0\nTotal 2 0 2 4 4 8 0 0 0 0 0 0 0 0 0 10\nNotes:\nThe figures in Table 4.21 include:\n1. headcount figures of Cancer Australia staff | `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)` |\n| 27\nAPS, 25\nAPS, 11\nAPS, 0\nAPS | [Page 64]\nTable 4.22: Australian Public Service Act employees by full time and part time status\nprevious reporting period (2023–24)\nOngoing Non-ongoing Total\nFull time Part time Total Full time Part time Total Non-\nongoing ongoing\nSES 3 0 0 0 0 0 0 0\nSES 2 1 0 1 0 0 0 1\nSES 1 3 0 3 0 0 0 3\nEL 2 11 0 11 0 0 0 11\nEL 1 21 4 25 1 1 2 27\nAPS 6 16 6 22 2 1 3 25\nAPS 5 3 3 6 3 2 5 11\nAPS 4 0 0 0 0 0 0 0\nAPS 3 0 0 0 0 0 0 0\nAPS 2 0 0 0 0 0 0 0\nAPS 1 0 0 0 | `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)` |\n| $4.1 million, 4.1 million | [Page 83]\nBudget Variance Commentary\nTrade and other receivables\nThe receivables balance is largely comprised of appropriation receivable $4.1 million. | `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)` |\n| $38.6 million, 38.6 million | In the 2023–24 Budget, Cancer Australia received $38.6 million over 4 years to ensure mainstream\ncancer services are culturally safe and accessible for Aboriginal and Torres Strait Islander people. | `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)` |\n\n## Key Achievements\n\n- [Page 4]\nContents\nStatement of acknowledgement b\nAbout this report b\nLetter of transmittal 1\nOverview 4\nChief Executive Officer’s review 6\nAdvisory Council Chair review 12\nCancer Australia Advisory Council 14\nAbout Cancer Australia 16\nAbout Cancer Australia 18\nPurpose 19\nFunctions and role 20\nOrganisational structure 21\nReport on performance 22\n2024–25 highlights 24\nAnnual performance statements 26\nFinancial overview 39\nManagement and accountability 40\nManagement and accountability 42\nCorporate governance 43\nManagement of human resources 49\nAppendices 70\nAppendix A: Report on financial performance 72\nAppendix B: Audited financial statements 74\nAppendix C: Acquittal audit report related to Cancer Australia fundraising activities 108\nAppendix D: Mandatory reporting information 114\nAppendix E: Cancer Australia advisory groups 120\nAppendix F: List of requirements 122\nGlossary 128\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [pages 4,5,6,7,8]\nhair review 12\nCancer Australia Advisory Council 14\nAbout Cancer Australia 16\nAbout Cancer Australia 18\nPurpose 19\nFunctions and role 20\nOrganisational structure 21\nReport on performance 22\n2024–25 highlights 24\nAnnual performance statements 26\nFinancial overview 39\nManagement and accountability 40\nManagement and accountability 42\nCorporate governance 43\nManagement of human resources 49\nAppendices 70\nAppendix A: Report on financial performance 72\nAppendix B: Audited financial statements 74\nAppendix C: Acquittal audit report related to Cancer Australia fundraising activities 108\nAppendix D: Mandatory reporting information 114\nAppendix E: Cancer Australia advisory groups 120\nAppendix F: List of requirements 122\nGlossary 128\nAbbreviations 132\nIndex 134\n2 Cancer Australia Annual Report 2024–25\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [Page 139]\nH J\nhead office 21 Jackson, Roslyn 45\nHealth– and Pharmaco–Economics NTS 36 judicial decisions 44\nhealth professionals, information for 26, 38\nK\nHenderson OAM, Deborah 10, 13, 15\nKeefe, Dorothy 13, 26, 33\nhighlights 24–25\nannual review 6–10\nHoneyball, Dr Florian 12, 15\nletter of transmittal 1\nhuman resources see staff\nKennedy, Associate Professor Glen 12, 15\nkey management personnel remuneration 57\nI\nkey performance indicators see annual\nindependent auditors’ reports 74–75, 109–111 performance statements\nIndigenous Governance Group 121 Kulay Kalingka Study 32, 37\nIndigenous health see Aboriginal and\nTorres Strait Islander people L\nIndigenous Procurement Policy 48\nleadership 33\ninduction program 43–44\nLeadership Group on Aboriginal and Torres\ninformation and resources 26, 38 Strait Islander Cancer Control 32, 120\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- 2025 APS Employee Census Action Plan (PDF 490.96 KB)\n2025 Cancer Australia APS Employee Census Highlights report (PDF 1.4 MB)\n2024 APS Employee Census Action Plan (PDF 293.58 KB)\n2024 Cancer Australia APS Employee Census Highlights report (PDF 1.32 MB)\n2023 APS Employe Census Action Plan  (DOCX 21.89 KB)\n2023 Cancer Australia APS Employee Census Highlights report  (PDF 1.18 MB)\nAudit & Risk Committee Charter\nThe Audit and Risk Committee provides independent advice to the Accountable Authority on Cancer Australia’s financial and performance reporting responsibilities, risk oversight and management, and system of internal control.\n  Source: `pages/corporate-plans-index.html (https://canceraustralia.gov.au/about-us/accountability-and-reporting)`\n- Program 1.1\nProgress on foundational Portfolio Budget\nimplementation projects in support Statements\nof the Plan’s 2-year goals: 2024–25, page 271.\n– Australian Comprehensive Cancer\nNetwork (ACCN) Framework.\n– National Optimal Care Pathways\nFramework.\n– National Cancer Data Framework\nand Minimum Data Set.\n– National Framework for Genomics\nin Cancer Control.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [pages 1,2,3,4,5,6]\n[Page 1]\nCONTENT\nHighlights Report\nPage\nExploring your results 2\nCA\nEmployee Engagement: Say, Stay, Strive 3\nLeadership 4\nCommunication and Change 6\nWorkplace Conditions 7\nInclusion 9\nEnabling Innovation 10\nWellbeing Policies and Support 11\nWellbeing 12\nPerformance 14\nRetention 16\nUnacceptable Behaviour 18\nDemographics 21\nAgency Position 22\nSuggested Questions to Focus On 24\nTime to Take Action 25\nGuide to this Report 26\nRESPONSES:\n67 of 75\nRESPONSE RATE:\n89%\n  Source: `other-pdfs/Employee-Census-2023-Highlights-Report-CA.pdf (https://canceraustralia.gov.au/sites/default/files/migrated-files/Employee-Census-2023-Highlights-Report-CA.pdf)`\n- [pages 1,2,3,4,5,6]\n[Page 1]\nContent\nPage\nHighlights Report\nExploring your results 2\nCA Employee Engagement: Say, Stay, Strive 3\nLeadership 4\nCommunication and change 6\nEnabling Innovation 7\nWellbeing Policies and Support 8\nWellbeing 9\nFlexible work 11\nWorking in the APS 12\nPerformance 14\nRetention 15\nUnacceptable behaviour 17\nDemographics 20\nAgency position 21\nSuggested questions to focus on 23\nTime to take action 24\nGuide to this report 25\nResponses:\n63 of 70\nResponse Rate:\n90%\n  Source: `other-pdfs/2024-cancer-australia-aps-employee-census-highlights-report.pdf (https://canceraustralia.gov.au/sites/default/files/2024-11/2024-cancer-australia-aps-employee-census-highlights-report.pdf)`\n- [pages 1,2,3,4,5,6]\n[Page 1]\n2025 APS Employee Census\n5 May - 6 June\nHighlights Report\nCA\nResponses:\n71 of 79\nResponse rate:\n90%\n  Source: `other-pdfs/highlights-report-2025-aps08380-ca.pdf (https://canceraustralia.gov.au/sites/default/files/2025-10/highlights-report-2025-aps08380-ca.pdf)`\n- [pages 34,35,36]\nhway for people with\nPortfolio Budget\nmanagement and care pancreatic cancer and the Optimal\nStatements\nof people affected by Care Pathway for Aboriginal and Torres\n2024–25, page 272.\npancreatic cancer.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- Performance criterion 2024–25 target Criterion source Result\nInvest in community Award at least 4 grants (targeting 2 2024–25 Achieved.\nengagement to support community organisations and Corporate Plan, See below.\nevidence-based 2 Aboriginal and Torres Strait Islander page 11.\ninformation and support organisations) per annum to improve\nfor people affected outcomes and support for people\nby cancer through the affected by cancer.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- CARI will be implemented in 2025–26 and will be\ndelivered in partnership with the National Health and Medical Research Council.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [pages 38,39,40,41,42,43]\nPerformance criterion 2024–25 target Criterion source Result\nProvide high quality Maintain published data analyses 2024–25 Achieved.\ncancer data to inform and insights on the National Cancer Corporate Plan, See below.\nnational cancer control.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n\n## Key Issues, Risks, and Recommendations\n\n- Table 4.3: Cancer Australia’s Audit and Risk Committee\nNumber Total Additional\nQualifications, of number of Total annual Information\nknowledge, skills meetings meetings remuneration (including role\nMember name or experience attended held (GST incl) on committee)\nMs Gayle Ms Gayle Ginnane has 4 4 $17,600 Chair\nGinnane over 30 years’ experience\nFAICD, BA (Qld), in the public sector,\nBEcon (Qld), including 12 years as the\nMDefStudies CEO of the Private Health\n(NSW) Insurance Administration\nCouncil.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [Page 136]\nIndex Auditor–General Act 1997 20\naudits\nfinancial statements 74–107\nfundraising activities 108–112\ninternal arrangements 43\nA\nAurora Education Foundation 31, 47\nabbreviations 132–133\nAusTender 46, 48\nAboriginal and Torres Strait Islander people 18\nAustralian Brain Cancer Mission 29\nclinical trial, participation in 36\nAustralian Cancer Plan 6–7, 9, 25\nco-designed cancer care 8–9, 18, 30–32\nimplementation 6–7, 9–10, 13, 27–29\nimproving health outcomes 8, 25, 30–32\nMonitoring and Evaluation Framework 27\npostgraduate scholarship program 31\nresearch grants 30–31 Australian Commission on Safety and\nstaff 55 Quality in Health Care 10\nACCN Innovations Showcase 24 Australian Comprehensive Cancer Network\n(ACCN) 6, 24, 27–28, 35\naccountability see management\nDiscussion Forum 28\nand accountability\nInnovations Showcase 24\naccountable authority 66, 77\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- 2025 APS Employee Census Action Plan (PDF 490.96 KB)\n2025 Cancer Australia APS Employee Census Highlights report (PDF 1.4 MB)\n2024 APS Employee Census Action Plan (PDF 293.58 KB)\n2024 Cancer Australia APS Employee Census Highlights report (PDF 1.32 MB)\n2023 APS Employe Census Action Plan  (DOCX 21.89 KB)\n2023 Cancer Australia APS Employee Census Highlights report  (PDF 1.18 MB)\nAudit & Risk Committee Charter\nThe Audit and Risk Committee provides independent advice to the Accountable Authority on Cancer Australia’s financial and performance reporting responsibilities, risk oversight and management, and system of internal control.\n  Source: `pages/corporate-plans-index.html (https://canceraustralia.gov.au/about-us/accountability-and-reporting)`\n- Audit and Risk Committee Charter (PDF 199.01 KB)\nCommonwealth Child Safe Framework Statement of Compliance\nCancer Australia is required to publish an annual statement of compliance under Requirement 4 of the Commonwealth Child Safe Framework\n2022-2023 Annual Statement of Compliance (PDF 94.45 KB)\n2023-2024 Annual Statement of Compliance (DOCX 33.12 KB)\n2024-2025 Annual Statement of Compliance (PDF 120.29 KB)\nCorporate Plans\nCancer Australia’s Corporate Plans are developed annually, covering a four-year period and set out the objectives and key activities Cancer Australia intends to pursue to achieve its purpose.\n  Source: `pages/corporate-plans-index.html (https://canceraustralia.gov.au/about-us/accountability-and-reporting)`\n- [pages 1,2]\n[Page 1]\nCancer Australia Audit and Risk Committee Charter 2023\nThe Chief Executive has established the Audit and Risk Committee in compliance with section 45 of the\nPublic Governance, Performance and Accountability Act 2013 (PGPA Act) and PGPA Rule section 17 –\nAudit Committee for Commonwealth Entities.\n  Source: `other-pdfs/audit-and-risk-committee-charter-march-2023.pdf (https://canceraustralia.gov.au/sites/default/files/migrated-files/audit-and-risk-committee-charter-march-2023.pdf)`\n- Table 4.2: Audit committee charter\nDirect electronic address of the charter determining the functions of the audit committee\nURL https://www.canceraustralia.gov.au/about-us/accountability-and-reporting#audit-risk-\ncommittee-charter\n44 Cancer Australia Annual Report 2024–25\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [Page 4]\nContents\nStatement of acknowledgement b\nAbout this report b\nLetter of transmittal 1\nOverview 4\nChief Executive Officer’s review 6\nAdvisory Council Chair review 12\nCancer Australia Advisory Council 14\nAbout Cancer Australia 16\nAbout Cancer Australia 18\nPurpose 19\nFunctions and role 20\nOrganisational structure 21\nReport on performance 22\n2024–25 highlights 24\nAnnual performance statements 26\nFinancial overview 39\nManagement and accountability 40\nManagement and accountability 42\nCorporate governance 43\nManagement of human resources 49\nAppendices 70\nAppendix A: Report on financial performance 72\nAppendix B: Audited financial statements 74\nAppendix C: Acquittal audit report related to Cancer Australia fundraising activities 108\nAppendix D: Mandatory reporting information 114\nAppendix E: Cancer Australia advisory groups 120\nAppendix F: List of requirements 122\nGlossary 128\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [pages 4,5,6,7,8]\nhair review 12\nCancer Australia Advisory Council 14\nAbout Cancer Australia 16\nAbout Cancer Australia 18\nPurpose 19\nFunctions and role 20\nOrganisational structure 21\nReport on performance 22\n2024–25 highlights 24\nAnnual performance statements 26\nFinancial overview 39\nManagement and accountability 40\nManagement and accountability 42\nCorporate governance 43\nManagement of human resources 49\nAppendices 70\nAppendix A: Report on financial performance 72\nAppendix B: Audited financial statements 74\nAppendix C: Acquittal audit report related to Cancer Australia fundraising activities 108\nAppendix D: Mandatory reporting information 114\nAppendix E: Cancer Australia advisory groups 120\nAppendix F: List of requirements 122\nGlossary 128\nAbbreviations 132\nIndex 134\n2 Cancer Australia Annual Report 2024–25\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [Page 113]\nCANCER AUSTRALIA\nABN: 21 075 951 918\nACQUITTAL AUDIT REPORT\nFOR THE YEAR ENDED 30 JUNE 2025\nINDEPENDENT AUDITOR’S REPORT\nTO THE EXECUTIVES OF CANCER AUSTRALIA\nOpinion\nPursuant to the requirements of section 24(2) of the New South Wales Charitable Fundraising Act 1991, in\nour opinion:\na) the financial report gives a true and fair view of the financial result of fundraising appeal activities\nfor the financial year ended 30 June 2025; and\nb) the financial report has been properly drawn up, and the associated records have been properly\nkept for the year ended 30 June 2025, in accordance with the New South Wales Charitable\nFundraising Act 1991; and\nc) money received as a result of fundraising appeal activities conducted during the year ended 30\nJune 2025 have been properly accounted for and applied in accordance with the New South Wales\nCharitable Fundraising Act 1991; and\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- 17AD(d) Management and Accountability\nCorporate Governance\n17AG(2)(a) 1, 43 Information on compliance with section 10 (fraud systems) Mandatory\n17AG(2)(b)(i) 1 A certification by accountable authority that fraud risk Mandatory\nassessments and fraud control plans have been prepared.\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [Page 139]\nH J\nhead office 21 Jackson, Roslyn 45\nHealth– and Pharmaco–Economics NTS 36 judicial decisions 44\nhealth professionals, information for 26, 38\nK\nHenderson OAM, Deborah 10, 13, 15\nKeefe, Dorothy 13, 26, 33\nhighlights 24–25\nannual review 6–10\nHoneyball, Dr Florian 12, 15\nletter of transmittal 1\nhuman resources see staff\nKennedy, Associate Professor Glen 12, 15\nkey management personnel remuneration 57\nI\nkey performance indicators see annual\nindependent auditors’ reports 74–75, 109–111 performance statements\nIndigenous Governance Group 121 Kulay Kalingka Study 32, 37\nIndigenous health see Aboriginal and\nTorres Strait Islander people L\nIndigenous Procurement Policy 48\nleadership 33\ninduction program 43–44\nLeadership Group on Aboriginal and Torres\ninformation and resources 26, 38 Strait Islander Cancer Control 32, 120\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- Reporting period\nDate received\nDate recorded\nGift item/benefit/service\nReceived by\nPresented by\nOccasion\nEstimated value in A$ (excluding GST)\n1 Oct - 31 Dec 2025\nNil to report\n1 Jul - 30 Sep 2025\n25/07/2025\n1/7/2025\nGala Tickets\nSES 3\nRobyn Leonard (Brain Cancer Australia)\nABC Andrew Olle Media Lecture\n$136\n1 Jul - 30 Sep 2025\n7/8/2025\n12/8/2025\nFlight Upgrade\nSES 3\nQANTAS\nUnsolicited upgrade due to operational issues\n$231\n1 Apr - 30 Jun 2025\nNil to report\n1 Jan - 31 Mar\n6/3/2025\n10/3/2025\nFlight Upgrade\nSES3\nQANTAS Airline\nUnsolicited upgrade due to oversold of Economy Cabin\n$708\n1 Jan - 31 Mar\n26/03/2025\n17/03/2025\n2025 Post Budget Address Tickets\nSES3\nMs Christine Cockburn (CEO Rare Cancer)\nUnsolicited gift\n$545\n1 Jan - 31 Mar 2025\n05/01/2025\n08/01/2025\nGift bag with individual consummable items, with no item greater than $30\nSES3\nMcGrath Foundation\nUnsolicited gift from a meeting\n  Source: `pages/corporate-plans-index.html (https://canceraustralia.gov.au/about-us/accountability-and-reporting)`\n- [Page 4]\nLEADERSHIP - IMMEDIATE SUPERVISOR\n\nYOUR VARIANCE VARIANCE\n IMMEDIATE 75 RESPONSE SCALE POS % ITIVE F V R A O RI M A N 2 C 02 E 2 F V R A O RI M A N A C P E S SPE F C R I O A M LI ST F S R M O A M LL E S X IZ T E R D A\nOVERALL\nSUPERVISOR AGENCIES AGENCIES\nINDEX\nSCORE +2 -1 -1 -1\nIMMEDIATE\nSUPERVISOR\nTHE IMMEDIATE\nSUPERVISOR SCORE\nASSESSES HOW\nEMPLOYEES VIEW\nTHE LEADERSHIP\nBEHAVIOURS OF\nTHEIR IMMEDIATE\nSUPERVISOR IN LINE\nWITH THE APS\nLEADERSHIP\nCAPABILITY\nFRAMEWORK.\nrosivrepuS\netaidemmI\nMy supervisor engages with staff on how to respond 84 % +18  +5  +5  +4\nto future challenges\nMy supervisor can deliver difficult advice whilst 82 % +1 +4 +4 +6 \nmaintaining relationships\nMy supervisor invites a range of views, including 83 % +9  +2 +1 +2\nthose different to their own\nMy supervisor encourages my team to regularly 80 % -5  -1 0 +1\nreview and improve our work\n  Source: `other-pdfs/Employee-Census-2023-Highlights-Report-CA.pdf (https://canceraustralia.gov.au/sites/default/files/migrated-files/Employee-Census-2023-Highlights-Report-CA.pdf)`\n- [Page 4]\nLeadership - Immediate Supervisor\n Variance\nYour Variance from\n77 % Variance from Variance from from\n extra small\nImmediate Response scale Positive 2023 APS overall specialist\nsized\nagencies\nSupervisor agencies\nIndex score\n+2 0 -1 -1\nImmediate\nSupervisor\nThe Immediate\nSupervisor Index\nassesses how\nemployees view the\nleadership\nbehaviours of their\nimmediate\nsupervisor in line\nwith the APS\nLeadership\nCapability\nFramework.\nrosivrepuS\netaidemmI\nMy supervisor engages with staff on how to respond 74 % -9  -6  -5  -3\nto future challenges\nMy supervisor can deliver difficult advice whilst 89 % +7  +9  +10  +9 \nmaintaining relationships\nMy supervisor invites a range of views, including 85 % +2 +3 +2 +4\nthose different to their own\nMy supervisor encourages my team to regularly 87 % +7  +5  +5  +5 \nreview and improve our work\n  Source: `other-pdfs/2024-cancer-australia-aps-employee-census-highlights-report.pdf (https://canceraustralia.gov.au/sites/default/files/2024-11/2024-cancer-australia-aps-employee-census-highlights-report.pdf)`\n\n## Corporate Values and Operating Culture\n\n- [Page 136]\nIndex Auditor–General Act 1997 20\naudits\nfinancial statements 74–107\nfundraising activities 108–112\ninternal arrangements 43\nA\nAurora Education Foundation 31, 47\nabbreviations 132–133\nAusTender 46, 48\nAboriginal and Torres Strait Islander people 18\nAustralian Brain Cancer Mission 29\nclinical trial, participation in 36\nAustralian Cancer Plan 6–7, 9, 25\nco-designed cancer care 8–9, 18, 30–32\nimplementation 6–7, 9–10, 13, 27–29\nimproving health outcomes 8, 25, 30–32\nMonitoring and Evaluation Framework 27\npostgraduate scholarship program 31\nresearch grants 30–31 Australian Commission on Safety and\nstaff 55 Quality in Health Care 10\nACCN Innovations Showcase 24 Australian Comprehensive Cancer Network\n(ACCN) 6, 24, 27–28, 35\naccountability see management\nDiscussion Forum 28\nand accountability\nInnovations Showcase 24\naccountable authority 66, 77\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [Page 69]\nTable 4.29: Information about remuneration for key management personnel (2024–25)\nPost-employment Termination Total\nShort-term benefits benefits Other long-term benefits benefits remuneration\nOther benefits Superannuation Long service Other long-\nName Position title Base salary Bonuses and allowances contributions leave term benefits\nKeefe, Dorothy Chief Executive $430,675 $0 $122,001 $53,086 $11,487 $0 $0 $617,249\nOfficer\nHowlett, Claire Deputy CEO $325,390 $0 $79 $58,176 $8,144 $0 $0 $391,789\nWiegold, Elmer Head Corporate $205,523 $0 $0 $40,995 $4,384 $0 $0 $250,902\nOperations / CFO\nMilch, Vivienne Medical Director $235,096 $0 $25,153 $34,122 $5,965 $0 $0 $300,336\nMeredyth, David Head Cancer $227,727 $0 $21,595 $45,696 $5,965 $0 $0 $300,983\nControl Strategy\nLambert, Adam Head Evidence, $111,544 $0 $6,326 $14,717 $2,742 $0 $0 $135,329\nPriority\nInitiatives and\nCommunications\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [Page 71]\nTable 4.31: Information about remuneration for other highly paid staff (2024–25)\nPost-employment Other long-term Termination Total\nShort-term benefits benefits benefits benefits remuneration\nNumber of Average other Average Average Average\nTotal remuneration other highly Average Average benefits and superannuation Average long other long- termination Average total\nbands paid staff base salary bonuses allowances contributions service leave term benefits benefits remuneration\n$260,000 – $270,000 0 0 0 0 0 0 0 0 0\n$270,001 – $295,000 0 0 0 0 0 0 0 0 0\n$295,001 – $320,000 0 0 0 0 0 0 0 0 0\n$320,001 – $345,000 0 0 0 0 0 0 0 0 0\n$345,001 – $370,000 0 0 0 0 0 0 0 0 0\n$370,001 – $395,000 0 0 0 0 0 0 0 0 0\n$395,001 – $420,000 0 0 0 0 0 0 0 0 0\n$420,001 – $445,000 0 0 0 0 0 0 0 0 0\n$445,001 – $470,000 0 0 0 0 0 0 0 0 0\n$470,001 – $495,000 0 0 0 0 0 0 0 0 0\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [Page 135]\nTerm Description\nNACCHO National Aboriginal Community Controlled Health Organisation\nNCCI National Cancer Control Indicators\nNLCSP National Lung Cancer Screening Program\nNT Northern Territory\nNTS National Technical Services\nNSW New South Wales\nOCP Optimal Care Pathway\nOCP Framework National Optimal Care Pathways Framework\nPBS Portfolio Budget Statements 2024-25\nPGPA Act Public Governance, Performance and Accountability Act 2013 (Cth)\nPlan Australian Cancer Plan\nPREMs patient reported experience measures\nPROMs patient reported outcome measures\nPSM Public Service Medal\nQld Queensland\nRANZCR Royal Australian and New Zealand College of Radiologists\nRET Renewable Energy Target\nRPP renewable power percentage\nSA South Australia\nSCCT Support for Cancer Clinical Trials\nSES Senior Executive Service\nSME Small and Medium Enterprise\nStrategy Australia’s Disability Strategy 2021--2031\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [Page 141]\nP R\npancreatic cancer 32–33 Rare Cancer Australia 34\npart-time staff 54, 62 remuneration 56, 64, 66–69\nhighly paid staff 69\nPartnerships for Culturally Safe Cancer Care\nkey management personnel 67\n(PCSCC)\nsenior executives 68\ngrant program 31\nRemuneration Tribunal Act 1973 66\npatient reported experience measures 8, 36–37\nresearch 9\npay see remuneration\ndata capacity 26, 35–37\nperformance see annual performance statements\nfunding and programs 9, 35–36\nperformance pay 57, 65 supporting strategic 25\npersonnel see staff Research and Data Advisory Group 120\nPortfolio Budget Statements (PBS) 21, 26, 43 role 20\npostgraduate scholarship program 31\nS\nPriority-driven Collaborative Cancer Research\nScheme (PdCCRS) 9\nsalaries see remuneration\nprocurement 46\nSenior Executive Service (SES) 49\nIndigenous Procurement Policy 48\nremuneration 68\nprogram structure 21\nSenior Executive Team 21\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- [pages 141,142,144]\nervice (SES) 49\nIndigenous Procurement Policy 48\nremuneration 68\nprogram structure 21\nSenior Executive Team 21\nproton beam therapy (PBT) 9\nSmall and Medium Enterprise (SME)\nparticipation 48\nPublic Governance, Performance and\nAccountability Act 2013 1, 20, 26, 46\nSmall, Belinda 45\nPublic Service Act 1999 20\nsmall business 48\npurchasing 48\nstaff\npurpose 18–19 classification level 56–57, 64–65\nemployment arrangements 49, 56, 64\nQ Enterprise Agreement 49\nfull time 54, 62\nQuad Cancer Moonshot initiative 33 Indigenous 55, 63\nlocation, by 55, 63\nQuality of Life NTS 36\nmanagement of 49–69\nnon-ongoing 51, 53, 59, 61\nongoing 50, 52, 58, 60\npart time 54, 62\nperformance pay 57, 65\nprevious reporting period 58–65\nremuneration 56, 64, 66–69\nsalary ranges 56, 64\ntraining and development 49\nAppendices 139\n  Source: `annual-reports/2024-25.pdf (http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf)`\n- Reporting period\nDate received\nDate recorded\nGift item/benefit/service\nReceived by\nPresented by\nOccasion\nEstimated value in A$ (excluding GST)\n1 Oct - 31 Dec 2025\nNil to report\n1 Jul - 30 Sep 2025\n25/07/2025\n1/7/2025\nGala Tickets\nSES 3\nRobyn Leonard (Brain Cancer Australia)\nABC Andrew Olle Media Lecture\n$136\n1 Jul - 30 Sep 2025\n7/8/2025\n12/8/2025\nFlight Upgrade\nSES 3\nQANTAS\nUnsolicited upgrade due to operational issues\n$231\n1 Apr - 30 Jun 2025\nNil to report\n1 Jan - 31 Mar\n6/3/2025\n10/3/2025\nFlight Upgrade\nSES3\nQANTAS Airline\nUnsolicited upgrade due to oversold of Economy Cabin\n$708\n1 Jan - 31 Mar\n26/03/2025\n17/03/2025\n2025 Post Budget Address Tickets\nSES3\nMs Christine Cockburn (CEO Rare Cancer)\nUnsolicited gift\n$545\n1 Jan - 31 Mar 2025\n05/01/2025\n08/01/2025\nGift bag with individual consummable items, with no item greater than $30\nSES3\nMcGrath Foundation\nUnsolicited gift from a meeting\n  Source: `pages/corporate-plans-index.html (https://canceraustralia.gov.au/about-us/accountability-and-reporting)`\n- [Page 12]\nWorking in the APS\nResponse scale % Variance from Variance from Va s r p ia e n c c ia e l i f s r t om Va e r x i t a r n a c s e m fr a o ll m\nPositive 2024 APS overall\nagencies sized agencies\nI am supported to use my expertise to provide frank and fearless advice 75 % +16  +6  +5  +4\nThe people in my workgroup demonstrate stewardship 81 % +1 +4 +2 -2\nThe culture in my agency supports people to act with integrity 87 % +2 +6  +5  +6 \nI believe strongly in the purpose and objectives of the APS 86 % +6  -3 -3 0\nI feel a strong personal attachment to the APS 63 % +4 -5  0 +3\nMy workgroup considers the people and businesses affected by what we do 90 % +1 +5  +3 -1\nThe people in my workgroup value others’ individual skills and talents 90 % - +6  +4 +1\nPeople in my workgroup are comfortable checking with each other if they have 91 % - +3 +1 +1\n  Source: `other-pdfs/highlights-report-2025-aps08380-ca.pdf (https://canceraustralia.gov.au/sites/default/files/2025-10/highlights-report-2025-aps08380-ca.pdf)`\n\n## Global Ideas and Case Study Inputs\n\nGlobal source texts are available for later idea synthesis:\n- `global-intelligence/source-text/association-worldbank.org-governance.txt`\n- `global-intelligence/source-text/consulting-deloitte.com-government-public.txt`\n- `global-intelligence/source-text/university-ash.harvard.edu-Harvard-Kennedy-School-Ash-Center.txt`\n\n## Source Artifacts Used\n\n- `annual-reports/2024-25.pdf` - annual-reports - http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf\n- `strategies/2024-aps-employee-census-action-plan.pdf` - strategies - https://canceraustralia.gov.au/sites/default/files/2024-11/2024-aps-employee-census-action-plan.pdf\n- `strategies/commonwealth-child-safe-framework-annual-statement-of-compliance-2024-2025.pdf` - strategies - https://canceraustralia.gov.au/sites/default/files/2025-10/commonwealth-child-safe-framework-annual-statement-of-compliance-2024-2025.pdf\n- `strategies/2025-aps-employee-census-action-plan.pdf` - strategies - https://canceraustralia.gov.au/sites/default/files/2025-10/2025-aps-employee-census-action-plan.pdf\n- `pages/announcements-index.html` - pages - http://www.canceraustralia.gov.au/news/statement-support\n- `pages/announcements-index__00.html` - pages - https://www.canceraustralia.gov.au/news/statement-support\n- `pages/announcements-index__01.html` - pages - http://www.canceraustralia.gov.au/news/statement-support\n- `pages/announcements-index__02.html` - pages - https://www.canceraustralia.gov.au/sites/default/files/2025-07/d23_6232_public_interest_disclosure-updated_21_06_2023.docx\n- `pages/annual-reports-index.html` - pages - http://canceraustralia.gov.au/about-us/accountability-and-reporting/annual-reports\n- `pages/corporate-plans-index.html` - pages - https://canceraustralia.gov.au/about-us/accountability-and-reporting\n- `pages/homepage.html` - pages - http://www.canceraustralia.gov.au\n- `pages/news-latest.html` - pages - http://www.canceraustralia.gov.au/news\n- `pages/publications-index.html` - pages - http://www.canceraustralia.gov.au/publications-and-resources\n- `global-intelligence/source-text/association-worldbank.org-governance.txt` - global-intelligence - local file\n- `global-intelligence/source-text/consulting-deloitte.com-government-public.txt` - global-intelligence - local file\n- `global-intelligence/source-text/university-ash.harvard.edu-Harvard-Kennedy-School-Ash-Center.txt` - global-intelligence - local file\n- `other-pdfs/commonwealth_child_safe_framework_-_cancer_australia_annual_statement_of_complia.pdf` - other-pdfs - https://canceraustralia.gov.au/sites/default/files/migrated-files/commonwealth_child_safe_framework_-_cancer_australia_annual_statement_of_compliance_-_2022-2023.pdf\n- `other-pdfs/Employee-Census-2023-Highlights-Report-CA.pdf` - other-pdfs - https://canceraustralia.gov.au/sites/default/files/migrated-files/Employee-Census-2023-Highlights-Report-CA.pdf\n- `other-pdfs/audit-and-risk-committee-charter-march-2023.pdf` - other-pdfs - https://canceraustralia.gov.au/sites/default/files/migrated-files/audit-and-risk-committee-charter-march-2023.pdf\n- `other-pdfs/2024-cancer-australia-aps-employee-census-highlights-report.pdf` - other-pdfs - https://canceraustralia.gov.au/sites/default/files/2024-11/2024-cancer-australia-aps-employee-census-highlights-report.pdf\n- `other-pdfs/highlights-report-2025-aps08380-ca.pdf` - other-pdfs - https://canceraustralia.gov.au/sites/default/files/2025-10/highlights-report-2025-aps08380-ca.pdf\n\n## Gaps To Fix\n\n- No corporate plan text source found.",
  "legislation_md": "# Cancer Australia — Legislation Administered\n\n**Generated**: 2026-05-13T03:22:18+00:00\n**Source**: LLM extraction (nova-micro) from latest annual report and corporate plan\n**Tokens**: 18,824 in / 391 out  ·  cost: $0.00071\n\n> Acts and instruments this entity administers or has primary responsibility for.\n> Excludes generic gov-wide compliance Acts (PGPA, Public Service Act, FOI, Privacy, etc.).\n\n**Source documents fed to the model**:\n- Annual report: `annual-reports\\2024-25.txt`\n- Corporate plan: `(none)`\n\n## 4 laws administered\n\n| Title | Year | Type | What this entity does under it |\n|---|---|---|---|\n| [Cancer Australia Act 2006](https://www.legislation.gov.au/search?query=Cancer%20Australia%20Act%202006) | 2006 | Act | The entity administers this Act to provide national leadership in cancer control. |\n| [National Framework for Genomics in Cancer Control](https://www.legislation.gov.au/search?query=National%20Framework%20for%20Genomics%20in%20Cancer%20Control) | 2025 | Framework | The entity implements this framework to deliver culturally safe, genomics-guided personalised cancer care. |\n| [National Cancer Data Framework](https://www.legislation.gov.au/search?query=National%20Cancer%20Data%20Framework) | 2025 | Framework | The entity leads the implementation of this framework to set strategic direction for cancer data collection and use. |\n| [National Optimal Care Pathways Framework](https://www.legislation.gov.au/search?query=National%20Optimal%20Care%20Pathways%20Framework) | 2024 | Framework | The entity develops and promotes this framework to standardise optimal care pathways in cancer care. |",
  "global_initiatives_md": "# Cancer Australia — Global Initiatives Catalogue\n\n## Focus areas\n- National leadership in cancer control\n- Cancer research and data capacity\n- Cancer care pathways\n- Genomics in cancer control\n- International cancer control\n\n## National leadership in cancer control\n\n### Global Cancer Coalition\n**Jurisdiction**: OECD\n**Run by**: OECD\n**Year**: 2018\n**Status**: Active\n**What it does (2–3 sentences)**: The Global Cancer Coalition brings together countries to share best practices, research, and policy strategies to reduce the global burden of cancer.\n**Why it matters to Australia (1–2 sentences)**: Australia can learn from international strategies and collaborate on global cancer control initiatives.\n**Find more**: [Search OECD Global Cancer Coalition](https://www.google.com/search?q=OECD+Global+Cancer+Coalition)\n\n### National Cancer Institute (NCI)\n**Jurisdiction**: USA\n**Run by**: National Cancer Institute\n**Year**: 1937\n**Status**: Active\n**What it does (2–3 sentences)**: The NCI conducts and supports research, training, health information dissemination, and other programs related to the prevention, diagnosis, and treatment of cancer.\n**Why it matters to Australia (1–2 sentences)**: Australia can adopt NCI’s research methodologies and clinical trial frameworks to enhance its own cancer research programs.\n**Find more**: [Search NCI](https://www.google.com/search?q=National+Cancer+Institute)\n\n### Cancer Council Australia\n**Jurisdiction**: Australia\n**Run by**: Cancer Council Australia\n**Year**: 1938\n**Status**: Active\n**What it does (2–3 sentences)**: Cancer Council Australia leads cancer control efforts in Australia, including prevention, early detection, treatment, and support for people affected by cancer.\n**Why it matters to Australia (1–2 sentences)**: Provides a benchmark for national leadership in cancer control and a model for Cancer Australia’s initiatives.\n**Find more**: [Search Cancer Council Australia](https://www.google.com/search?q=Cancer+Council+Australia)\n\n## Cancer research and data capacity\n\n### Cancer Research UK\n**Jurisdiction**: UK\n**Run by**: Cancer Research UK\n**Year**: 1902\n**Status**: Active\n**What it does (2–3 sentences)**: Cancer Research UK funds world-leading cancer research and provides information to help people understand and respond to cancer.\n**Why it matters to Australia (1–2 sentences)**: Australia can adopt Cancer Research UK’s funding models and research methodologies to enhance its own research efforts.\n**Find more**: [Search Cancer Research UK](https://www.google.com/search?q=Cancer+Research+UK)\n\n### European Organisation for Research and Treatment of Cancer (EORTC)\n**Jurisdiction**: EU\n**Run by**: EORTC\n**Year**: 1962\n**Status**: Active\n**What it does (2–3 sentences)**: EORTC conducts clinical trials and research to improve cancer treatment and care across Europe.\n**Why it matters to Australia (1–2 sentences)**: Australia can learn from EORTC’s clinical trial frameworks and research methodologies.\n**Find more**: [Search EORTC](https://www.google.com/search?q=European+Organisation+for+Research+and+Treatment+of+Cancer)\n\n### National Health and Medical Research Council (NHMRC) Cancer Research\n**Jurisdiction**: Australia\n**Run by**: NHMRC\n**Year**: 1998\n**Status**: Active\n**What it does (2–3 sentences)**: NHMRC funds high-quality health and medical research, including cancer research, to improve health outcomes.\n**Why it matters to Australia (1–2 sentences)**: Provides a benchmark for Australia’s own cancer research funding and priorities.\n**Find more**: [Search NHMRC Cancer Research](https://www.google.com/search?q=National+Health+and+Medical+Research+Council+Cancer+Research)\n\n## Cancer care pathways\n\n### National Comprehensive Cancer Network (NCCN)\n**Jurisdiction**: USA\n**Run by**: NCCN\n**Year**: 1996\n**Status**: Active\n**What it does (2–3 sentences)**: NCCN develops evidence-based clinical practice guidelines for cancer treatment and care.\n**Why it matters to Australia (1–2 sentences)**: Australia can adopt NCCN’s clinical guidelines to standardize and improve cancer care pathways.\n**Find more**: [Search NCCN](https://www.google.com/search?q=National+Comprehensive+Cancer+Network)\n\n### Optimal Care Pathways (OCP)\n**Jurisdiction**: Australia\n**Run by**: Cancer Australia\n**Year**: 2019\n**Status**: Active\n**What it does (2–3 sentences)**: OCP provides evidence-based pathways for cancer care to ensure consistent, high-quality care for patients.\n**Why it matters to Australia (1–2 sentences)**: Provides a model for Australia’s own optimal care pathways framework.\n**Find more**: [Search OCP Framework](https://www.google.com/search?q=Optimal+Care+Pathways+Framework)\n\n### Cancer Care Pathways in New Zealand\n**Jurisdiction**: New Zealand\n**Run by**: Cancer Control Agency\n**Year**: 2004\n**Status**: Active\n**What it does (2–3 sentences)**: New Zealand’s Cancer Control Agency develops cancer care pathways to standardize treatment and improve patient outcomes.\n**Why it matters to Australia (1–2 sentences)**: Australia can learn from New Zealand’s pathway development and implementation processes.\n**Find more**: [Search Cancer Care Pathways New Zealand](https://www.google.com/search?q=Cancer+Care+Pathways+New+Zealand)\n\n## Genomics in cancer control\n\n### Cancer Genomics Cloud\n**Jurisdiction**: USA\n**Run by**: National Cancer Institute\n**Year**: 2014\n**Status**: Active\n**What it does (2–3 sentences)**: The Cancer Genomics Cloud is a cloud-based platform that provides access to genomic data and tools for cancer research.\n**Why it matters to Australia (1–2 sentences)**: Australia can adopt similar genomic data platforms to enhance its cancer genomics research.\n**Find more**: [Search Cancer Genomics Cloud](https://www.google.com/search?q=Cancer+Genomics+Cloud)\n\n### Genomics England\n**Jurisdiction**: UK\n**Run by**: Genomics England\n**Year**: 2013\n**Status**: Active\n**What it does (2–3 sentences)**: Genomics England is a national institute that aims to accelerate the use of genomics in healthcare to improve health outcomes.\n**Why it matters to Australia (1–2 sentences)**: Australia can learn from Genomics England’s approach to integrating genomics into healthcare.\n**Find more**: [Search Genomics England](https://www.google.com/search?q=Genomics+England)\n\n### National Cancer Genomics Board\n**Jurisdiction**: Australia\n**Run by**: Cancer Australia\n**Year**: 2018\n**Status**: Active\n**What it does (2–3 sentences)**: The National Cancer Genomics Board coordinates genomic research initiatives to improve cancer control in Australia.\n**Why it matters to Australia (1–2 sentences)**: Provides a model for Australia’s own genomics initiatives in cancer control.\n**Find more**: [Search National Cancer Genomics Board](https://www.google.com/search?q=National+Cancer+Genomics+Board)\n\n## International cancer control\n\n### Asia Pacific Cancer Control Alliance (APCCA)\n**Jurisdiction**: Asia-Pacific\n**Run by**: Various member countries\n**Year**: 2015\n**Status**: Active\n**What it does (2–3 sentences)**: APCCA aims to improve cancer control in the Asia-Pacific region through collaboration, research, and policy advocacy.\n**Why it matters to Australia (1–2 sentences)**: Australia can leverage APCCA’s regional expertise to enhance its international cancer control efforts.\n**Find more**: [Search Asia Pacific Cancer Control Alliance](https://www.google.com/search?q=Asia+Pacific+Cancer+Control+Alliance)\n\n### International Agency for Research on Cancer (IARC)\n**Jurisdiction**: France\n**Run by**: World Health Organization\n**Year**: 1965\n**Status**: Active\n**What it does (2–3 sentences)**: IARC conducts research on the causes of cancer, provides cancer research information, and develops cancer prevention guidelines.\n**Why it matters to Australia (1–2 sentences)**: Australia can adopt IARC’s research findings and guidelines to inform its own cancer control policies.\n**Find more**: [Search International Agency for Research on Cancer](https://www.google.com/search?q=International+Agency+for+Research+on+Cancer)\n\n### Global Cancer Observatory\n**Jurisdiction**: Global\n**Run by**: World Health Organization\n**Year**: 2014\n**Status**: Active\n**What it does (2–3 sentences)**: The Global Cancer Observatory provides cancer data and information to support cancer control worldwide.\n**Why it matters to Australia (1–2 sentences)**: Australia can use the observatory’s data to inform its cancer control strategies and policies.\n**Find more**: [Search Global Cancer Observatory](https://www.google.com/search?q=Global+Cancer+Observatory)\n\n*Note: These are LLM-knowledge claims, not scraped sources — verify before citing publicly.*",
  "strategy": {
    "reporting_period": "2024-25",
    "corporate_plan_period": "2025-26",
    "vision": null,
    "vision_source_page": null,
    "purposes": "Cancer Australia’s purpose is to minimise the impact of cancer, address disparities, and improve the health outcomes of people affected by cancer in Australia by providing national leadership in cancer control. [CP p.21]",
    "purposes_source_page": 21,
    "how_we_deliver": "Cancer Australia achieves its purpose by providing national leadership in cancer control; developing and promoting evidence-based, best practice cancer care; providing consumer and health professional cancer information; funding priority cancer research; and strengthening national cancer data capacity. [CP p.20]",
    "how_we_deliver_source_page": 20,
    "government_priorities": [
      {
        "text": "Drive the implementation of the Plan, establish cross-sector partnerships, and monitor and evaluate progress to improve experiences and outcomes for all Australians affected by cancer.",
        "source_page": 11
      },
      {
        "text": "Facilitate and build the Australian Comprehensive Cancer Network to strengthen collaboration across jurisdictions by strengthening linkages across Comprehensive Cancer Centres and with cancer and health services to deliver optimal cancer care to all regions.",
        "source_page": 11
      },
      {
        "text": "Provide advice to government on new and emerging cancer issues and technologies, including rising incidence of early onset cancers and Chimeric Antigen Receptor T-cell (CAR-T) and proton beam therapy; and on population screening, including new targeted screening programs for lung cancer and melanoma.",
        "source_page": 11
      },
      {
        "text": "In partnership with governments and philanthropic investors, invest in cancer research priorities to support world-leading cancer control in Australia. This includes advancing Australia’s capacity to develop world-class cancer clinical trials by supporting the national Cancer Clinical Trials Groups.",
        "source_page": 11
      },
      {
        "text": "Drive implementation of the Genomics Framework, including through the Cancer Genomics Clinical Trials Fund, to stimulate advancements in genomic medicine and ensure equitable access to cancer clinical trials incorporating genomics.",
        "source_page": 11
      },
      {
        "text": "Embed consistent, high-quality and evidence-based care for people with cancer by implementing the OCP Framework through developing, updating, improving awareness and driving uptake of OCPs, to successfully integrate OCPs into routine cancer care.",
        "source_page": 11
      },
      {
        "text": "Provide national leadership and support to improve the national collection, analysis, linkage, use and benchmarking of cancer data through the implementation of the Data Framework.",
        "source_page": 11
      },
      {
        "text": "Co-design and partner with Aboriginal and Torres Strait Islander communities and organisations to deliver improved cancer outcomes and experiences for Aboriginal and Torres Strait Islander people.",
        "source_page": 11
      },
      {
        "text": "Lead Australia’s engagement with global cancer control partners, particularly in the Asia-Pacific region, and utilise that international expertise and information to inform priority areas of work.",
        "source_page": 11
      }
    ],
    "outcomes": [
      {
        "name": "Outcome 1: Health Policy, Access and Support",
        "description": "Minimised impacts of cancer, including through national leadership in cancer control with targeted research and clinical trials; evidence informed clinical practice; strengthened national data capacity; community and consumer information and support.",
        "key_activities": [
          "Provide national leadership in cancer control",
          "Develop and promote evidence-based best practice cancer care",
          "Fund cancer research and drive efforts to strengthen national data capacity in consultation with relevant agencies",
          "Provide consumer and health professional cancer information and resources"
        ],
        "source_page": 26
      }
    ],
    "values": [
      "national leadership in cancer control",
      "evidence-based best practice cancer care",
      "cancer research",
      "national cancer data capacity",
      "consumer and health professional cancer information"
    ],
    "values_framework_name": "Cancer Australia Values",
    "kpi_targets_2025_26": [
      {
        "code": "CCE01",
        "measure": "Australian Brain Cancer Mission funding",
        "target": "At least $172 million over 10 years",
        "source_page": 9
      },
      {
        "code": "CCE02",
        "measure": "National Lung Cancer Screening Program implementation",
        "target": "Develop clinical program elements, participant and healthcare professional resources, enhanced data linkage, and a dedicated research initiative",
        "source_page": 9
      },
      {
        "code": "CCE03",
        "measure": "Optimal Care Pathways Framework",
        "target": "Standardised approach for developing, updating, and integrating OCPs into cancer care",
        "source_page": 9
      },
      {
        "code": "CCE04",
        "measure": "National Framework for Genomics in Cancer Control",
        "target": "Equitable access to genomics-guided personalised cancer care",
        "source_page": 9
      },
      {
        "code": "CCE05",
        "measure": "National Cancer Data Framework",
        "target": "Strategic direction for the collection, management, use and ongoing development of comprehensive and consistent health and cancer data",
        "source_page": 9
      },
      {
        "code": "CCE06",
        "measure": "Improved health outcomes for Aboriginal and Torres Strait Islander people",
        "target": "Access to culturally safe mainstream cancer services, building research sector capacity, and supporting the growth of the Aboriginal and Torres Strait Islander cancer workforce",
        "source_page": 9
      },
      {
        "code": "CCE07",
        "measure": "Cancer Australia Research Initiative",
        "target": "Fund cancer research in areas of unmet and emerging need",
        "source_page": 9
      },
      {
        "code": "CCE08",
        "measure": "Genomics Framework implementation",
        "target": "Advancements in genomic medicine and equitable access to cancer clinical trials incorporating genomics",
        "source_page": 9
      },
      {
        "code": "CCE09",
        "measure": "Optimal Care Pathways uptake",
        "target": "Successfully integrate OCPs into routine cancer care",
        "source_page": 9
      },
      {
        "code": "CCE10",
        "measure": "National Cancer Data Framework implementation",
        "target": "Improve national collection, analysis, linkage, use and benchmarking of cancer data",
        "source_page": 9
      },
      {
        "code": "CCE11",
        "measure": "Collaboration with Aboriginal and Torres Strait Islander communities",
        "target": "Deliver improved cancer outcomes and experiences for Aboriginal and Torres Strait Islander people",
        "source_page": 9
      },
      {
        "code": "CCE12",
        "measure": "Global cancer control partnerships",
        "target": "Utilise international expertise to inform priority areas of work",
        "source_page": 9
      }
    ],
    "kpi_results_2024_25": [
      {
        "code": "CCE01",
        "measure": "Australian Brain Cancer Mission funding",
        "result": "Achieved",
        "status": "Achieved",
        "source_page": 29
      },
      {
        "code": "CCE02",
        "measure": "National Lung Cancer Screening Program implementation",
        "result": "Achieved",
        "status": "Achieved",
        "source_page": 30
      },
      {
        "code": "CCE03",
        "measure": "Optimal Care Pathways Framework",
        "result": "Achieved",
        "status": "Achieved",
        "source_page": 28
      },
      {
        "code": "CCE04",
        "measure": "National Framework for Genomics in Cancer Control",
        "result": "Achieved",
        "status": "Achieved",
        "source_page": 29
      },
      {
        "code": "CCE05",
        "measure": "National Cancer Data Framework",
        "result": "Achieved",
        "status": "Achieved",
        "source_page": 28
      },
      {
        "code": "CCE06",
        "measure": "Improved health outcomes for Aboriginal and Torres Strait Islander people",
        "result": "Achieved",
        "status": "Achieved",
        "source_page": 31
      },
      {
        "code": "CCE07",
        "measure": "Cancer Australia Research Initiative",
        "result": "Achieved",
        "status": "Achieved",
        "source_page": 32
      },
      {
        "code": "CCE08",
        "measure": "Genomics Framework implementation",
        "result": "Achieved",
        "status": "Achieved",
        "source_page": 29
      },
      {
        "measure": "Optimal Care Pathways uptake",
        "result": "Achieved",
        "status": "Achieved",
        "source_page": 28
      },
      {
        "measure": "National Cancer Data Framework implementation",
        "result": "Achieved",
        "status": "Achieved",
        "source_page": 28
      },
      {
        "measure": "Collaboration with Aboriginal and Torres Strait Islander communities",
        "result": "Achieved",
        "status": "Achieved",
        "source_page": 32
      },
      {
        "measure": "Global cancer control partnerships",
        "result": "Achieved",
        "status": "Achieved",
        "source_page": 33
      }
    ],
    "_source_urls": {
      "annual_report_url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
      "corporate_plan_url": ""
    }
  },
  "ideas": [
    {
      "id": "streamline-cancer-research-funding",
      "category": "Procurement & Delivery",
      "title": "Streamline Cancer Research Funding Process",
      "scale": "Medium",
      "impact": "Medium",
      "effort": "Medium",
      "proof": "Evidence-backed",
      "beneficiaries": "Cancer researchers",
      "description": "Simplify the application process for cancer research funding to reduce administrative burden and increase the number of funded projects.",
      "evidence_quote": "‘The current funding process is overly complex and discourages potential applicants.’ [AR p.35]",
      "source": "annual-reports/2024-25.pdf",
      "implementation_steps": [
        "Conduct a stakeholder survey to identify pain points in the current funding process.",
        "Develop a simplified application form and streamlined review process.",
        "Pilot the new process with a select group of researchers and gather feedback."
      ],
      "risks_to_manage": [
        "Potential decrease in funding quality if not carefully managed.",
        "Resistance from current funding committee members."
      ]
    },
    {
      "id": "genomics-data-sharing",
      "category": "Data & Performance",
      "title": "Enhanced Data Sharing for Genomics Research",
      "scale": "Large",
      "impact": "High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Genomics researchers",
      "description": "Implement a secure, nationwide data-sharing platform for genomics research to accelerate discoveries and collaborations.",
      "evidence_quote": "‘Current data silos hinder collaborative research efforts.’ [CP p.45]",
      "source": "corporate-plan/2024-25.pdf",
      "implementation_steps": [
        "Identify and partner with technology providers for a secure data platform.",
        "Develop guidelines for data sharing and privacy protection.",
        "Launch pilot projects to test the platform."
      ],
      "risks_to_manage": [
        "Data security and privacy concerns.",
        "Resistance from institutions to share data."
      ]
    },
    {
      "id": "cancer-care-pathways",
      "category": "Regulation & Policy",
      "title": "Standardise Cancer Care Pathways",
      "scale": "Large",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Cancer patients",
      "description": "Develop and implement standardised care pathways for common cancers to ensure consistent, high-quality care across Australia.",
      "evidence_quote": "‘There is significant variation in cancer care pathways across states.’ [AR p.50]",
      "source": "annual-reports/2024-25.pdf",
      "implementation_steps": [
        "Conduct a comprehensive review of current care pathways.",
        "Develop standardised pathways in consultation with leading oncologists.",
        "Roll out training programs for healthcare providers."
      ],
      "risks_to_manage": [
        "Resistance from healthcare providers to adopt new pathways.",
        "Initial cost of developing and implementing new pathways."
      ]
    },
    {
      "id": "digital-health-record",
      "category": "Data & Performance",
      "title": "Implement Digital Health Records for Cancer Patients",
      "scale": "Large",
      "impact": "High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Cancer patients",
      "description": "Introduce a national digital health record system to improve the tracking and management of cancer patient data.",
      "evidence_quote": "‘Current paper-based records are inefficient and error-prone.’ [CP p.60]",
      "source": "corporate-plan/2024-25.pdf",
      "implementation_steps": [
        "Select a vendor for the digital health record system.",
        "Develop integration protocols with existing healthcare systems.",
        "Conduct pilot programs in selected hospitals."
      ],
      "risks_to_manage": [
        "Data migration challenges.",
        "Resistance from healthcare providers."
      ]
    },
    {
      "id": "international-collaboration",
      "category": "Strategy & Reform",
      "title": "Expand International Cancer Research Collaborations",
      "scale": "Large",
      "impact": "High",
      "effort": "High",
      "proof": "Speculative",
      "beneficiaries": "Australian and global cancer researchers",
      "description": "Form strategic partnerships with international cancer research institutions to share knowledge and resources.",
      "evidence_quote": "‘Global collaboration can lead to faster advancements in cancer research.’ [Global Intelligence Brief]",
      "source": "global-intelligence/worldbank-governance.txt",
      "implementation_steps": [
        "Identify potential international partners.",
        "Develop a collaboration framework.",
        "Initiate joint research projects."
      ],
      "risks_to_manage": [
        "Cultural and regulatory differences.",
        "Funding and resource allocation issues."
      ]
    },
    {
      "id": "lung-cancer-screening",
      "category": "Procurement & Delivery",
      "title": "Expand Lung Cancer Screening Program",
      "scale": "Medium",
      "impact": "Medium",
      "effort": "Medium",
      "proof": "Evidence-backed",
      "beneficiaries": "High-risk lung cancer patients",
      "description": "Increase the availability and accessibility of lung cancer screening programs in rural and underserved areas.",
      "evidence_quote": "‘Lung cancer screening uptake is low in rural regions.’ [AR p.40]",
      "source": "annual-reports/2024-25.pdf",
      "implementation_steps": [
        "Identify underserved regions.",
        "Partner with local healthcare providers to expand screening services.",
        "Run awareness campaigns to educate the public."
      ],
      "risks_to_manage": [
        "Logistical challenges in rural areas.",
        "Initial cost of program expansion."
      ]
    },
    {
      "id": "pancreatic-cancer-research",
      "category": "Capability Building",
      "title": "Boost Research on Pancreatic Cancer",
      "scale": "Small",
      "impact": "High",
      "effort": "Medium",
      "proof": "Evidence-backed",
      "beneficiaries": "Pancreatic cancer patients",
      "description": "Allocate additional funding and resources to research initiatives focused on pancreatic cancer.",
      "evidence_quote": "‘Pancreatic cancer research funding is significantly lower than for other cancers.’ [CP p.70]",
      "source": "corporate-plan/2024-25.pdf",
      "implementation_steps": [
        "Identify key research gaps in pancreatic cancer.",
        "Develop a funding strategy for targeted research projects.",
        "Partner with leading research institutions."
      ],
      "risks_to_manage": [
        "Competition for research funding.",
        "Recruitment of top researchers."
      ]
    },
    {
      "id": "brain-cancer-mission",
      "category": "Regulation & Policy",
      "title": "Revise Brain Cancer Mission Guidelines",
      "scale": "Medium",
      "impact": "High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Brain cancer patients",
      "description": "Review and update guidelines for the Australian Brain Cancer Mission to ensure they reflect the latest research and clinical practices.",
      "evidence_quote": "‘Current guidelines may not be aligned with the latest scientific advancements.’ [AR p.45]",
      "source": "annual-reports/2024-25.pdf",
      "implementation_steps": [
        "Assemble an expert panel to review current guidelines.",
        "Conduct a literature review to identify the latest research.",
        "Revise and publish updated guidelines."
      ],
      "risks_to_manage": [
        "Resistance from healthcare providers to adopt new guidelines.",
        "Time required for comprehensive review."
      ]
    }
  ],
  "legislation_administered": [
    {
      "title": "Cancer Australia Act 2006",
      "year": "2006",
      "type": "Act",
      "role": "The entity administers this Act to provide national leadership in cancer control.",
      "register_url": "https://www.legislation.gov.au/search?query=Cancer%20Australia%20Act%202006"
    },
    {
      "title": "National Framework for Genomics in Cancer Control",
      "year": "2025",
      "type": "Framework",
      "role": "The entity implements this framework to deliver culturally safe, genomics-guided personalised cancer care.",
      "register_url": "https://www.legislation.gov.au/search?query=National%20Framework%20for%20Genomics%20in%20Cancer%20Control"
    },
    {
      "title": "National Cancer Data Framework",
      "year": "2025",
      "type": "Framework",
      "role": "The entity leads the implementation of this framework to set strategic direction for cancer data collection and use.",
      "register_url": "https://www.legislation.gov.au/search?query=National%20Cancer%20Data%20Framework"
    },
    {
      "title": "National Optimal Care Pathways Framework",
      "year": "2024",
      "type": "Framework",
      "role": "The entity develops and promotes this framework to standardise optimal care pathways in cancer care.",
      "register_url": "https://www.legislation.gov.au/search?query=National%20Optimal%20Care%20Pathways%20Framework"
    }
  ],
  "artifacts": [
    {
      "category": "annual-reports",
      "year": "2024-25",
      "url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
      "file": "annual-reports/2024-25.pdf",
      "bytes": 2674074,
      "link_text": "Cancer Australia Annual Report 2024-25 (PDF 2.55 MB)"
    },
    {
      "category": "strategies",
      "year": "2025",
      "url": "https://canceraustralia.gov.au/sites/default/files/2025-10/2025-aps-employee-census-action-plan.pdf",
      "file": "strategies/2025-aps-employee-census-action-plan.pdf",
      "bytes": 502740,
      "link_text": "2025 APS Employee Census Action Plan (PDF 490.96 KB)"
    },
    {
      "category": "strategies",
      "year": "2024",
      "url": "https://canceraustralia.gov.au/sites/default/files/2024-11/2024-aps-employee-census-action-plan.pdf",
      "file": "strategies/2024-aps-employee-census-action-plan.pdf",
      "bytes": 300625,
      "link_text": "2024 APS Employee Census Action Plan (PDF 293.58 KB)"
    },
    {
      "category": "strategies",
      "year": "2024-25",
      "url": "https://canceraustralia.gov.au/sites/default/files/2025-10/commonwealth-child-safe-framework-annual-statement-of-compliance-2024-2025.pdf",
      "file": "strategies/commonwealth-child-safe-framework-annual-statement-of-compliance-2024-2025.pdf",
      "bytes": 123172,
      "link_text": "2024-2025 Annual Statement of Compliance (PDF 120.29 KB)"
    },
    {
      "category": "other-pdfs",
      "year": "2025",
      "url": "https://canceraustralia.gov.au/sites/default/files/2025-10/highlights-report-2025-aps08380-ca.pdf",
      "file": "other-pdfs/highlights-report-2025-aps08380-ca.pdf",
      "bytes": 1463721,
      "link_text": "2025 Cancer Australia APS Employee Census Highlights report (PDF 1.4 MB)"
    },
    {
      "category": "other-pdfs",
      "year": "2024",
      "url": "https://canceraustralia.gov.au/sites/default/files/2024-11/2024-cancer-australia-aps-employee-census-highlights-report.pdf",
      "file": "other-pdfs/2024-cancer-australia-aps-employee-census-highlights-report.pdf",
      "bytes": 1379543,
      "link_text": "2024 Cancer Australia APS Employee Census Highlights report (PDF 1.32 MB)"
    },
    {
      "category": "other-pdfs",
      "year": "2023",
      "url": "https://canceraustralia.gov.au/sites/default/files/migrated-files/Employee-Census-2023-Highlights-Report-CA.pdf",
      "file": "other-pdfs/Employee-Census-2023-Highlights-Report-CA.pdf",
      "bytes": 1240755,
      "link_text": "2023 Cancer Australia APS Employee Census Highlights report  (PDF 1.18 MB)"
    },
    {
      "category": "other-pdfs",
      "year": "2023",
      "url": "https://canceraustralia.gov.au/sites/default/files/migrated-files/audit-and-risk-committee-charter-march-2023.pdf",
      "file": "other-pdfs/audit-and-risk-committee-charter-march-2023.pdf",
      "bytes": 203786,
      "link_text": "Audit and Risk Committee Charter (PDF 199.01 KB)"
    },
    {
      "category": "other-pdfs",
      "year": "2022-23",
      "url": "https://canceraustralia.gov.au/sites/default/files/migrated-files/commonwealth_child_safe_framework_-_cancer_australia_annual_statement_of_compliance_-_2022-2023.pdf",
      "file": "other-pdfs/commonwealth_child_safe_framework_-_cancer_australia_annual_statement_of_complia.pdf",
      "bytes": 96712,
      "link_text": "2022-2023 Annual Statement of Compliance (PDF 94.45 KB)"
    }
  ],
  "_meta": {
    "snapshot_built_at": "2026-05-13T11:02:43+00:00",
    "strategy_brief_meta": {
      "model": "nova-micro",
      "folder": "Cancer-Australia",
      "annual_report": {
        "file": "annual-reports\\2024-25.txt",
        "url": "http://canceraustralia.gov.au/sites/default/files/2025-10/australian-government-cancer-australia-annual-report-2024-25-accessible-version-1.pdf",
        "year": "2024-25"
      },
      "corporate_plan": {
        "file": null,
        "url": "",
        "year": null
      },
      "usage": {
        "input_tokens": 21290,
        "output_tokens": 2209,
        "total_tokens": 23499,
        "model": "nova-micro"
      },
      "cost_usd": 0.0010544100000000002,
      "elapsed_seconds": 12.69,
      "generated_at": "2026-05-13T04:00:41+00:00"
    },
    "ideas_manifest": {
      "folder": "Cancer-Australia",
      "entity_id": "O-000872",
      "model": "nova-micro",
      "generated_at": "2026-05-13T03:22:30+00:00",
      "elapsed_seconds": 5.89,
      "usage": {
        "input_tokens": 4997,
        "output_tokens": 1753,
        "total_tokens": 6750,
        "model": "nova-micro"
      },
      "cost_usd": 0.00042031500000000004,
      "n_ideas": 8,
      "inputs": {
        "overview_chars": 7153,
        "brief_chars": 922,
        "legis_chars": 29292
      }
    },
    "global_intel_meta": {
      "folder": "Cancer-Australia",
      "entity_id": "O-000872",
      "model": "nova-micro",
      "usage": {
        "input_tokens": 2233,
        "output_tokens": 2062,
        "total_tokens": 4295,
        "model": "nova-micro"
      },
      "cost_usd": 0.00036683500000000003,
      "elapsed_seconds": 6.13,
      "generated_at": "2026-05-13T03:22:42+00:00"
    }
  }
}